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Development of a DNA Vaccine Against Streptococcus mutans: a Novel Approach to
Immunization Against Dental Caries
Thomas K. Han
ABSTRACT
Streptococcus mutans is the main causative agent of dental caries, which is a
widespread infectious disease. A number of surface molecules are involved in the
pathogenicity of this organism, including adherence and aggregation factors. The wallassociated protein A (WapA) of Streptococcus mutans GS-5 was previously
demonstrated to be a sucrose-dependent adherence and aggregation factor, and is a larger
precursor to extracellular antigen A (AgA), a candidate antigen for a dental caries
vaccine.
The full-length wapA gene and a C-terminal truncated version agA encoding the
AgA were cloned into the mammalian expression vector pcDNA 3.1/V5/His-TOPO. The
above constructs were mixed with a cationic lipid and used to transfect Chinese hamster
ovary (CHO) cells. Transient expression of the wapA and agA genes was observed at 24
h post-transfection, as shown by Western immunoblot analysis. In CHO, cells WapA
containing the membrane and wall-spanning region was found in apoptotic bodies,
whereas the soluble AgA, which lacked the hydrophobic region, was found in
extracellular medium.
A higher salivary IgA level was observed in mice immunized with the pcDNAix

wapA vaccine as compared to those immunized with the pcDNA-agA vaccine.
Furthermore, the anti-WapA antibody inhibited S. mutans sucrose-dependent adherence,
suggesting potential protection of the tooth against S. mutans colonization, while antiAgA had no significant effect. Indeed, prediction and analysis of protein epitopes
showed that WapA contains highly promiscuous MHC-II binding motifs that are absent
from AgA. Immunodot assay confirmed that WapA bound biotin-labeled dextran,
whereas AgA did not. These data indicated that full-length wall-associated WapA is a
better candidate vaccine antigen than the soluble AgA.
In co-immunization studies pcDNA-ctb was preferable to pcDNA-il-5 as genetic
adjuvant. A comparable secondary response was obtained by priming with either
pcDNA-wapA or WapA followed by a WapA boost, thus demonstrating the pcDNAwapA as a valid contender primary vaccine. The successful utilization of the caries
DNA-based vaccine protocol would represent a highly significant new approach to this
important worldwide health problem.

x

INTRODUCTION
Background of Dental Caries
Dental caries is one of the most prevalent and costly chronic infectious diseases in
humans. Despite improvement in dental hygiene and advances in caries research over the
past decades, dental caries has been experienced by over 90 percent of all adults in the
U.S. and over 80 percent of children by age 17, resulting in billion of dollars in health
expenditures per year (53, 79, 140). In recent years, caries prevalence and distribution
has shifted from being circulated evenly among the population, to disproportionately
affecting individuals in economically-challenged populations with more severe forms of
caries (20, 108). The incidence of dental caries is high in industrialized countries and on
the rise in developing countries (4, 71). The risk of severe dental caries is increased in
elderly people who are showing root-surface caries and in other specific groups such as
those who suffer from hypo-salivation due to drug-induced side effects, systemic disease
such as Sjogren’s Syndrome, and tumor patients receiving irradiation therapy (2, 3, 13,
128).
The etiologic role of mutans streptococci (MS) in dental caries was established in
Keyes’ experiment in 1960, showing direct evidence that these organisms are the primary
etiologic agents. MS has been divided into eight serotypes designated a-h based on
differences of carbohydrates in the cell wall (9, 11, 97). DNA homology analysis further
clarified MS into seven distinct species – known as Streptococcus mutans (serotypes c,e
1

and f), S. rattus (serotype b), S. cricetus (serotype a), S. sobrinus (serotypes d and g), S.
ferus (serotype C), and S macacae (serotype c) and S. downei (serotype H) (8, 17, 18,
138). These organisms have the ability to colonize the tooth surface, build up dental
plaque by aggregating homologous and heterologous bacteria, and produce lactic acid
which attacks the enamel. Of these species, S. mutans has been implicated as the major
and most common of the two main etiological agents of human dental caries (37, 73,
135), the other being called S. sobrinus. S. mutans was first described by Clarke in 1924
after he isolated an organism that he felt to be from the initial carious lesions in humans
(15). Clarke named S. mutans based on his observation that the organism formed
different colony morphology with the change of growth media.
As with a large number of infectious diseases, dental caries is preventable by
immunization. This was demonstrated in animal studies, but the prospect for a human
dental caries vaccine using whole organisms or components of S. mutans has been
hampered by the presence of antigens that are cross-reactive with proteins in human
cardiac tissue (46). Consequently, much effort has been focused on developing
recombinant vaccine antigens. Through this process, heart reactive antigens can be
avoided or modified to eliminate the heart cross-reactive epitopes. With decades of
research on S. mutans by dedicated researchers around the world, a number of proteins
involved in colonization have been studied as important candidate dental vaccine
antigens. One concern is how to make them affordable to large populations, especially
since most of the populations at risk are from developing countries, or from low
socioeconomic groups in industrialized nations.
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Virulence Factors of S. mutans and Approaches for Development of Anti-caries
Vaccine
A number of surface molecules contribute to the pathogenicity of the MS
organism including adherence and aggregation factors (37). With recombinant DNA
technology and advances in mucosal immunology, a number of virulence factors
involved in S. mutans, a principal causative agent of dental caries, have been
characterized, cloned and tested for the ability to induce a protective response through
induction of mucosal immunity and production of specific salivary secretory IgA (sIgA).
Today, much progress has been made in the field of dental caries vaccines based on the
virulence factors involved in the S. mutans colonization of the tooth and build-up of
dental plaque (Fig. 1). The factors tested to reduce dental caries in an animal model
include: (1) A 190 kDa salivary adhesin called “AgI/II”; (2) Glucosyltransferase (GTF);
(3) A glucan binding protein (GBP), (4) A 29 kDa extracellular antigen A (AgA), also
known as antigen III; and (5) Wall-associated protein A (WapA), a precursor to the
extracellular AgA (59, 64). These receptors could be blocked by vaccine-induced
antibodies, thus preventing the S. mutans from colonizing or accumulating in the oral
cavity. Recombinant DNA technology has been applied to clone the genes encoding the
above virulence factors for the production of recombinant antigen and peptide vaccines,
as well as avirulent recombinant organisms expressing the target antigen.

3

FIG. 1. Virulence factors of Streptococcus mutans during colonization and accumulation
in dental biofilms.

AgI/II
A 190 kDa major cell-surface protein antigen of S. mutans has been variously
known as AgI/II, P1 (33), Pac (93), and AgB (110) while designated as SpaA or PAg (55)
in S. sobrinus. AgI/II is involved in the initial bacterial adherence to tooth surfaces (28,
109). The AgI/II contains two internal repeating amino acid regions: 1) A-region with an
alanine-rich tandem repeat at N-terminal domain that can bind salivary components such
as sIgA, β2-microglobulin, histidine-rich polypeptides, a 60 kDa glycoprotein, high
molecular mass glycoproteins, lysozyme, lactoferrine, and 2) a P-region with a prolinerich repeat in the center of the molecule where an adhesion epitope resides (19, 68, 87).
4

Antibody to intact AgI/II (38, 54, 69) or peptides containing salivary-binding domain
epitopes (131) induced partial protection against dental caries in rodents, primates, and
humans. Passive immunization with the anti AgI/II antibody have shown reduced tooth
colonization with S. mutans (75, 76).
Glucosyltransferases (GTF)
Glucosyltransferases (GTF) in S. mutans are involved in the synthesis of
extracellular glucans, and its role in sucrose-enhanced cariogenicity was obtained from
the comparative insertional inactivation study of GTF genes (86, 144). Three gtf genes
encoding GtfB, GtfC and GtfD are responsible for glucan systhesis in S. mutans: GtfB
(118) synthesizes an α-1,3-linked insoluble glucan, while GtfD (44) is involved in the
formation of a soluble α-1,6 linked glucan. GtfC (100) synthesizes both insoluble and
soluble glucans. All GTF molecules contain a glucan-binding domain (GLU) on the Cterminal end and a sucrose-binding catalytic region (CAT) on the N-terminal part (84).
Salivary and serum antibodies to GTF were detected and significant protection from
dental caries was obtained by oral immunization with GTF in an animal model (126,
127).
Synthetic peptides from the catalytic or glucan-binding domains of GTF have
been shown to induce protection against experimental dental caries (132). The newly
formulated GTF peptide vaccine containing both the catalytic (CAT) and glucan-binding
(GLU) regions induced significantly enhanced levels of antibody to GTF than either a
CAT or GLU construct or coimmunization with CAT/GLU (133).
Glucan-binding proteins (GBP)
The S. mutans glucan-binding protein (GBP), which mediates binding of the
5

organisms to glucans synthesized by GTFs, is a virulence component in the development
of dental plaque, and a candidate for a human caries vaccine (72). S. mutans synthesizes
three glucan-binding proteins: GBP-A (110), GBP-B (123), and GBP-C (116). The
predominant S. mutans GBP-A with a molcular mass of 74 kDa was purified (112),
cloned, and sequenced (5). A S. mutans mutant insertionally inactivated in the gbpA was
analyzed in vitro to demonstrate the role of gbp in colonization (6). Both the mutant and
the parental type colonized smooth surfaces when grown in the presence of sucrose,
suggesting that S. mutans may involve more than one protein in glucan binding.
GBP-B secreted by S. mutans having a molecular mass of 59 kDa has been
purified (123) and compared structurally and antigenically to other GBP-A in S. mutans
and to the glucan-binding region of S. mutans glucosyltransferases. The GBP-B was
shown to be antigenically distinct from the GBP-A and induced significantly higher
salivary immune response in humans (123). GBP-C has an estimated molecular mass of
64 kDa and has no sequence similarities to GBP-A or GTF, but shows significant
sequence matching to the surface protein adhesion AgI/II (77, 125).
Antigen A (AgA)
One candidate vaccine antigen against dental caries is the S. mutans antigen A
(47, 110, 111), a proteolytic cleavage product of the large precursor wall-associated
protein A (WapA) (23, 113). Immunization with AgA-induced protection against caries
has been performed on cynomolgus monkeys (111) and mice (47) and has been
recognized as an anti-caries vaccine.
Wall-associated protein A
The gene encoding the wall-associated protein A (WapA), a precursor to the AgA,
6

was cloned and sequenced and proven to be involved in S. mutans sucrose-dependent
adherence and aggregation (23, 30). Insertional inactivation of the wapA gene resulted in
a significantly reduced sucrose-dependent adherence and aggregation, 40 and 52%,
respectively, of the wapA mutant (101). These findings suggest that the antibody to the
WapA or AgA may prevent dental caries by blocking both the colonization of the tooth
and the build-up of dental plaque by S. mutans.
A genomic library of S. mutans strain GS5 was constructed in our laboratory via
the shuttle vector Streptoccus-E. coli pSA3, and one clone was found to express the AgA
and its precursor, the WapA, by Western immunoblot analysis using a monoclonal
antibody against AgA (22). Subsequent sequence analysis of the gene showed that AgA
was derived from WapA by proteolytic cleavage. AgA previously shown by Russell
(110) was a good candidate dental vaccine antigen (47, 111). Immunization of rats and
monkeys conferred protection in these animals, with a reduction in carious lesions upon
infection of these animals with the S. mutans and feeding a cariogenic diet rich in sucrose
content.
Since WapA has been observed to have binding affinity for dextran, this protein
may be involved in glucan-mediated adherence and aggregation. Indeed, insertional
inactivation of wapA in S. mutans caused a significant decrease in sucrose-dependent
adherence and aggregation, by 40% and 50% respectively, as compared to the wild type
tested in parallel (101). The role of WapA in sucrose-dependent adherence and
aggregation was further demonstrated by cloning the wapA gene into S. gordonii, a
heterologous organism known to produce GTF but devoid of WapA. Expression of
WapA conferred to this organism the ability to attach to a culture dish and to aggregate
7

when grown in BHI containing 4% sucrose.
These observations provided an explanation of the protection obtained by
immunization with AgA (111). Perhaps the antibody raised against AgA blocked S.
mutans adherence and aggregation through binding to WapA. Through comparative
sequence analysis between the S. mutans strain GS5 and the S. mutans strain, Ingbritt
showed that the wapA gene was virtually identical in these strains, with the exception of
a 24 base pair deletion in the GS-5 strain. This is in agreement with the immunological
cross-reactivity of both strains with a rabbit anti-WapA antibody.
Isolation of WapA from the original E. coli recombinant clone designated 4B2
was not efficient; therefore, production of vaccine using this clone is not practical for
large scale immunization studies. To increase the expression of WapA and to facilitate
its isolation twelve wapA truncations were prepared by PCR amplification using primers
designed to delete various regions of the wapA gene. The truncated wapA genes,
designated wapA-A to wapA-L were cloned into the TA cloning vector pCR2.1-TOPO
(Invitrogen, Carlsbad, CA). Then they were excised by digestion with EcoRI and cloned
into the expression pGEX-6P-1 glutathione S-transferase (GST) fusion vector
(Pharmacia, Pittacaway, NJ). Cloning of a series of truncations of the wapA gene at the
N-terminal and C-terminal ends into the expression fusion vector pGEX-6P-1 glutathione
S-transferase (GST) demonstrated that the WapA and AgA reacted most strongly with a
rabbit antibody to the S. mutans WapA (146). The resulting plasmids were used
separately to transform E. coli BL21, a protease-deficient host strain for optimal
expression of recombinant proteins (Pharmacia).
PGEX-6P-1 contains a tac promoter for inducible high-level intracellular
8

expression, an internal lac Iq repressor for induction with isopropyl beta-Dthiogalactoside (IPTG), a PreScissionTM protease cleavage site for removal of the GST by
the PreScission protease enzyme, and an ampicillin resistance gene for selection of
recombinants. Of the 12 truncated wapA constructs, eight truncated wapA were found to
express proteins reacting with a rabbit anti-WapA. These included wapA-D to wapA-K.
The twelve wapA constructs are presented in Fig 2.

9

FIG. 2. Construction of truncated wapA. Numbers on the top of the line represent amino
acid positions. P is the promoter; SP is the signal peptide; PC is the protease cleavage
site; W is the Cell wall domain; and M is the Membrane-spanning domain.

Two of the clones constructed are of interest to the present study since they
expressed proteins corresponding to the wild type full-length WapA (clone WapA-E),
and a proteolytic cleavage site corresponding to the wild type extracellular AgA (clone
10

WapA-G) (146).
Passive immunization
Passive immunization has also been considered as a safe way to administer a
dental vaccine. Specific polyclonal and monoclonal antibodies prevent colonization of
the teeth by S. mutans. Lehner et al. (67) obtained a decrease in colonization by repeated
application of a monoclonal antibody to S. mutans AgI/II onto the teeth of Rhesus
monkeys. Passive immunization by oral administration of antibody to GTF-generated
protection was performed against S. mutans in the rat model (124). Other studies
demonstrated a more convenient means of passive immunization with immunized cow’s
milk. Application to mice showed a significant decrease in caries activity as compared to
animals receiving milk from unimmunized cows (91). Hatta and Michalek (42) showed
that a mouth rinse containing egg yolk IgY from chicken immunized with whole S.
mutans prevented the in vitro attachment of the S. mutans to saliva-coated hydroxyapatite
and reduced plaque formation in human volunteers. Ma et al. (76) ingeniously used a
tobacco plant as a means to mass produce monoclonal sIgA. Application of the plantderived antibody to human volunteers reduced plaque formation.
Advantages and disadvantages are associated with each type of vaccine. Longterm protection is obtained with active immunization using recombinant proteins or
peptides, but the response is variable between individuals. Rapid and dependable
protection is obtained with passive immunization; however, this protection is of limited
duration and frequent booster applications of antibodies may be required.
Advantages and Risks of DNA-based Immunization
DNA vaccines possess many of the most attractive aspects of modern vaccination
11

strategies and, therefore, offer potential solutions for other diseases for which
conventional vaccines have not yielded preventive measures. In comparison with
traditional vaccines, DNA-based vacccines offer a major advantage in terms of the ease
with which they can be constructed, modified, and purified. DNA vaccines are much
more stable and can be manufactured inexpensively on a large scale at high levels of
purity, which make them ideal prophylactic agents for use in developing countries (24,
129). Moreover, many different antigens from the same or different pathogens can be
cloned into a single vector. Therefore, making multivalent vaccines against pathogens
will decrease the number of vaccinations necessary, especially in children (27, 82).
Since DNA vaccines utilize the host cell’s transcriptional and translational
machinery to produce conformationally-specific antigens, the native conformation of
epitopes is conserved. An appropriate tertiary structure of protein conserved following
administration of a DNA vaccine is essential for the induction of conformationally
specific antibodies and protective immunity (36, 117). DNA vaccines can initiate both
cellular and humoral immune responses that are long lasting (24, 61, 103).
To date, DNA vaccines have not shown any of the possible adverse effects that
have been previously discussed as potential safety issues associated with DNA-based
immunization, which include the integration of the plasmid DNA into the host genome
(88, 141), leading to insertional mutation, induction of tumor formation by activation of
oncogenes, or auto-immune disease due to the induction of anti-DNA antibodies (66,
143). The safety of DNA vaccines in humans has been demonstrated in clinical trials
against several diseases and specific pathogens including cystic fibrosis, the hepatitis B
virus, herpes simplex virus, HIV, malaria, and cancer (26, 78, 136).
12

Mechanism of DNA Vaccines
The cellular and molecular mechanisms by which DNA-based immunizations
stimulate different types of T-cells have not been fully elucidated (64). The type of cells
transfected may vary depending on the route and method of DNA delivery (61). After
administration of antigen-encoding plasmid DNA, the vaccinee’s cells take up the DNA
molecules and transport them to the nucleus for transcription, with eventual export of the
transcribed messenger RNA to the cytoplasm for protein synthesis. In the nucleus, the
plasmid DNA is retained in an extra-chromosomal location and thus an expression of the
DNA is not influenced by surrounding chromosomal elements (39).
After translation at the ribosome, the antigens expressed intracellularly are
processed and presented to T cells in the context of antigen presenting cell’s (APC) MHC
class I or II molecules, depending on whether the antigen is processed through an
exogenous or endogenous pathway (106). An antibody response is induced by secretion
of expressed whole antigen or antigen peptides processed and presented to CD4+ T cells
on the cell surface with host MHC class II by antigen-presenting cells. Transfected APC
can also process the antigen to peptides which bind to an MHC class I molecule in the
ER. This complex moves via the golgi apparatus to the cell surface where it can
stimulate the cellular T cell response by activation of CD8+ cytotoxic T lyphocytes
(CTL), which directly lyse infected target cells (104) (Fig. 3).

13

FIG. 3. Genetic immunization: Mechanisms of antigen presentation.

Mucosal Immune System and Salivary Immunity in the Oral Cavity
The mucosal surfaces provide the principal immune defense against most human
pathogenic organisms. Mucosal immunity to a variety of antigens has been successfully
induced by immunization with protein or DNA vaccine through mucosal routes including
oral, nasal, and genito-rectal mucosa (134). The major antibody isotype found in external
secretions is sIgA, which can traverse epithelial membranes and help provide specific
immunity against pathogens, including cariogenic S. mutans (37). All the mucosal routes
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tested induced the production of secretory IgA in the immunized area, as well as at
distant mucosal surfaces (84, 90).
One major function of the mucosal immune system is to develop salivary IgA
antibodies in newborn infants (34). In mucosal immune systems, antigens or
microorganisms are taken up by specialized epithelial cells termed M cells which overlie
organized lymphoid follicles in tonsils and adenoids (Waldeyer’s ring) and on intestinal
Peyer’s patches. After uptake and transcellular transport by the M cells, the antigenic
materials are processed by underlying APCs, which present them to T helper cells. B
cells are stimulated by both T-cell activation and specific cytokines. B cells then,
differentiate into precursors of IgA-secreting plasma cells.
Following activation of B and T cells, the IgA-producing cells migrate to various
mucosal effector sites in the mucosal tissues including the stroma of the salivary glands,
where terminal differentiation of the B lymphoblasts into IgA-secreting plasma cells
occurs under the regulation of cytokines secreted by the T cells and epithelial cells. The
resulting polymeric IgA secreted in the salivary glands is taken up by a polymeric Ig
receptor on the basolateral surface of glandular epithelial cells and released into the saliva
with a bound secretory component to form salivary sIgA (81, 84, 90). Secreted salivary
IgA, in turn, interferes with S. mutans binding to tooth surfaces via both sucroseindependent and sucrose-dependent mechanisms (122). Immunoglobulins derived from
circulation pass through the gingival crevice into the oral cavity. These Igs, which
include IgM, IgG, and IgA, are proportionally lower than sIgA in saliva compared to
relative proportions in blood plasma (37).
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Caries Vaccine Route to Mucosal Immune Response
Depending on the route of immunization and the type of adjuvants utilized,
development of systemic and/or mucosal immunity can be favored. Induction of specific
mucosal immunity with production of specific salivary IgA is the goal of a dental vaccine
(37, 122). In mucosal system, the delivery of vaccine at any mucosal route results in the
induction of secretory IgA antibody at the delivery site as well as in the distant mucosal
sites (90). Oral immunization induces mucosal immune response in the gut-associated
lymphoid tissues (GALT), one of the principal inductive sites of sIgA antibody response,
which consist of the Peyer’s patches, the appendix, and solitary lymph nodes in the
gastrointestinal tract (83).
One drawback of the oral route for immunization is the damaging effects of
stomach acidity on the antigen. Thus, for oral immunization, the DNA vaccine has to be
encapsulated in enteric-coated tablets, or delivered by intra-oral Jet in the cheek, which is
also the case with protein vaccines (74). Rectal immunization is also an effective
inductive method for a mucosal immune response. Inductive potential of the rectal route
for salivary IgA responses was considered as an alternative route to mutans streptococcal
antigens (65).
Of all the mucosal routes tested, intra-nasal application of protein or DNA
vaccines has gained much popularity because it is not invasive (32, 38, 51, 92). This
route is especially convenient for the immunization of young children, who cannot yet
swallow enteric-coated tablets. Furthermore, unlike oral vaccine, a nasal vaccine does
not need to be encapsulated into enteric-coated tablets and consequently costs less to
prepare.
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Intranasal immunization with a S. mutans glucan-binding region of
glucosyltransferase (51) and a S. mutans-enriched fimbrial preparation (32) elicited
specific salivary IgA production and protective immunity. Intranasal immunization with
a DNA vaccine mixed with cationic lipids has been shown to be immunogenic.
Immunization of animals with a luciferase gene-DNA construct complexed with cationic
proteins resulted in the expression of luciferase in nasal tissue and an induction of a
systemic and humoral response after a single dose of the vaccine (58).
A number of adjuvants have been identified as stimulating a mucosal response to
protein or DNA vaccines. Adjuvants used in protein or peptide vaccines include cholera
toxin CT, cholera toxin B subunit (CTB), and a detoxified heat labile E. coli toxin (LT
R292G) (25, 142). Adjuvants used in DNA vaccines include liposome and various
cationic lipids (57, 58, 89, 98). Further stimulation of the immune response may be
obtained by co-immunization with genetic adjuvants consisting of plasmids encoding
cytokines, for example IL-4 or IL-10, to induce a Th2 type response, or IL-12 and/or a
granulocyte/macrophages colony stimulating factor to obtain a Th1 type of response (27,
92, 102, 139).
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MATERIALS AND METHODS
Structural Analysis of the Wall-associated Protein A Gene (wapA)
Antigenicity prediction algorithms of the WapA protein
The identification of B cell epitopes within a WapA protein sequence was
analyzed using four different prediction algorithms: Hopp-Woods, Parker, Welling, and
Kolaskar and Tongaonkar. The hydropathic profile of the WapA was calculated using
the Hopp-Woods algorithm (45), which is assumes that antigenic sites are primarily
hydrophilic at the surface of the protein. The Parker method (96) of prediction uses an
experimentally-determined hydrophilic scale of polypeptides derived from highperformance liquid chromatography (HPLC) parameters for the antigenic determinants.
Prediction of antigenic regions using the method of Welling (137) is based on the amino
acid composition in known antigenic peptides. A semi-empirical algorithm of Kolaskar
and Tongaonkar (60) uses data from both experimentally-determined epitopes and
physicochemical properties of amino acids for the prediction of antigenic determinants.
Prediction and analysis of MHC Class II binding regions
Potential T cell epitopes within AgA or WapA were identified using a matrixbased quantitative algorithm, publicly available on line at
http://www.imtech.res.in/raghava/propred/. The promiscuous binding regions were
located and quantified by a virtual matrix for 51 known MHC class II alleles. Binding
probabilities were set at a 3% threshold representing the 3% best scoring natural peptides.
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Analysis of wapA DNA sequence for glycosylation
Inappropriate glycosylation of bacterial proteins that results in conformational
change, thus causing alteration or loss of immunogenicity, has been of concern in DNA
vaccine preparation (48, 50). Potential glycosylation sites of the WapA protein were
evaluated. Prediction analysis of the N-glycosylation or O-glycosylation sites in WapA
based on the amino acid sequence was performed using NetNGlyc (35) or a NetOGlyc
prediction server (40, 41) available from URL: http://www.cbs.dtu.dk/services/.
Kozak sequences on the 5′ untranslated region (UTR) of the mRNA transcript
Initiation of translation is regulated by two fundamentally different mechanisms
in prokaryotes versus eukaryotes. In prokaryotes, the ribosome binding site (RBS), also
called the Shine-Dalgarno sequence, is engaged in its recognition by ribosome for
efficient and accurate translation of mRNA. In eukaryotes, however, a 40S ribosomal
subunit locates the initiator AUG codon by scanning the mRNA from the capped 5′ end
for the first AUG codon. It has been proven that a specific translational initiating
sequence called the Kozak consensus sequence is required for efficient translation
initiation in higher eukaryotes (62). Prokaryotes and some eukaryotes do not have a
Kozak sequence in their genes. To improve the translation efficiency of an expressed
wapA gene in mammalian hosts, the Kozak sequence ANNATGG was incorporated into
the wapA or agA forward primer in the process of caries DNA vaccine construction.
Codon usage
Codon usage was another topic of concern in bacterial DNA vaccine
development. There is a significant variation of codon usage bias in all organisms and
even between different genes. The difference in the codon usage can seriously limit the
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gene expression efficiency in a heterologous system. Codon optimization may be
considered in case the expression of the cloned gene is hampered due to the codon bias.
In such case, the alteration of rare codons of the foreign gene to make codon usage match
the available tRNA pool within the host cell may benefit by improving the expression
rate of heterologous genes.
Commonly used codons for S. mutans serotype c or wapA were determined from
the Codon Usage database located at www.kazusa.org.jp/codon/ and analyzed against
that of Homo sapiens or Mus musculus using the graphical codon usage analyzer
available at www.gcua.de. To locate cumulative low codon usage from wapA, each
codon position of wapA sequence was analyzed against the codon usage table of Homo
sapiens or Mus musculus using the codon usage analyzer. Codons were optimized
according to the codon usage tabulated from GenBank.
Identification and Characterization of Collagen Binding Properties by the WapA
Bacterial strains and growth conditions
The S. mutans strain used for cloning and expression was GS-5 (serotype c) (our
laboratory stock). S. mutans were grown in brain heart infusion (BHI) (Fisher Chemical
Co., Cincinnati, OH) broth at 37 °C without agitation, or on BHI agar containing 1.5%
agar at 37 °C in the presence of 10% CO2.
Specificity and localization of collagen binding domain
The nucleotide sequence and the deduced amino acid sequence of wapA indicated
that it contained a sequence specific collagen binding domain. Further analysis on the
specificity and localization of the collagen binding domain of the WapA was performed
with different functional domain algorithms including the NCBI Conserved Domain
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Database (CDD) (80) and Protein Families (Pfam) Applications (7) of these programs.
Structure prediction of collagen binding domain in WapA
In order to investigate the biochemical function of the putative collagen binding
domain, secondary structure analysis was carried out with the 3D-PSSM program (31,
56) using the amino acid sequence of the putative collagen binding domain in the WapA.
The predicted secondary structure was matched against the 3D-PSSM fold library
(http://www.sbg.bio.ic.ac.uk/~3dpssm/), which contains solved crystal structures. The
protein sequence was also scanned against the SCOP (Structural Classification of
Proteins) database, where protein domains are classified into four levels: family,
superfamily, fold, and class (72).
Cloning, expression and purification of recombinant collagen binding domain (rCBD) of
WapA
A C-terminal truncated version of wapA (wapA-G) encoding the AgA was used
as a clone for a putative recombinant collagen binding domain (rCBD). A 885 bp DNA
fragment of wapA lacking the promoter, the signal sequence, and the hydrophobic Cterminal region was cloned into the pGEX-6P-1 glutathione S-transferase (GST) fusion
vector and hosted in E. coli BL21 (DE3). rCBD was overexpressed by inoculating 500
mL of 2x YTA medium with 5 ml of overnight culture. The culture was continuously
grown at 37 °C until the A600 reached around 1. IPTG was added to a final concentration
of 1 mM to induce the expression of the cloned gene.
At 6 h post incubation, the cells were harvested by centrifugation at 7,700 x g for
10 min at 4 °C, and washed with 250 ml cold PBS containing 1 mM
Phenylmethylsulphonylfluoride (PMSF), followed by 1 min sonication on ice and
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centrifugation at 12,000 x g for 30 min. Solubilization of the fusion protein was aided by
mixing 20% Triton X-100 for 30 min. After centrifugation at 12,000 x g for 10 min at 4
°C, the supernatant was incubated on a rocker for 30 min at room temperature with 2 ml
of the 50% slurry of Glutathione Sepharose 4B (Pharmacia).
The mixture was transferred onto the Sepharose column, and the column was
washed with 15 ml of PBS. After the column was washed with 2.5 ml of PreScission
cleavage buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, pH
7.0), the PreScission Protease mix containing 20 µl of PreScission Protease with 230 µl
of PreScission cleavage buffer was loaded onto the column and incubated on a rocker at 5
°C for 4 h to cleave off the GST tag. The unbound rCBD protein was eluted with 800 µl
of PreScission cleavage buffer. Eluted fractions containing rCBD protein were analyzed
by SDS-PAGE.
Biotin Labeling
Biotin labeling of the purified rCBD was performed with Sulfo-NHS-LC-Biotin reagents
(Pierce, Rockford, IL) as follows. rCBD in an amine-free elution buffer (pH 7.2) was
mixed with a 10-fold molar excess of 10 mM sulfo-NHS-biotin reagent solution with the
protein, and the mixture was incubated at room temperature for 1 h. To remove free
biotin, the reaction solution was dialyzed against 3 changes (4 L each) of PBS (pH 7.3)
overnight using dialysis tubing with a nominal Molecular Weight Cut Off 's (MWCO)
12,000 – 14,000.
Dot Blot Collagen binding assay
To test the ability of WapA to bind to collagen, a soluble native type I collagen (Sigma,
St. Louis, MO) was diluted in PBS to 5 µg/ml and was dotted (10 µl per dot) onto a piece
22

of nitrocellulose membrane. The membrane was blocked by incubation with 5% skim
milk in PBS to which biotin-labeled rCBD was added, and incubated for 1 h at room
temperature. After extensive washes with PBST (PBS with 0.05% Tween 20), the bound
protein was detected by alkaline phosphatase-conjugated streptavidin (AP-streptavidin)
(Sigma) diluted 1:1,000 which was incubated in PBS for 1 h at room temperature. After
a final wash in PBS-T, the membrane was stained with a chromogenic substrate (25 mg
o-dianisidine tetrazotized, 25 mg Naphthyl acid phosphate in sodium borate buffer, pH
9.7 contaiing MgSO4-7H2O added at 1.2 mg per ml). Bovine Serum Albumin (BSA) on
the dot was tested in parallel as a negative control.
Solid Phase Binding Assay
To further evaluate the binding abilities of WapA to an immobilized native type I
collagen, an ELISA assay was carried out as a function of collagen concentration. Native
type I collagen (Sigma, St. Louis, MO) was diluted in PBS at a concentration of 5 µg/ml,
and coated onto 96 well microtiter plates (Immobilon IV from Dynex, Chantilly, VA)
overnight at 4 °C. After rinsing of the plate with PBS-T, the wells were blocked with 200
µl of 10% skim milk in PBS containing 0.02% sodium azide, for 1 h at room temperature.
100 µl of various dilutions (1 µg to 12 µg) of biotin-labeled, purified rCBD without a
GST tag was added separately to the wells and the plate was incubated at 37 °C for 1 h.
The wells were washed with PBS-T and incubated with AP-streptavidin diluted
1:20,000 in PBS for 1 h at room temperature. The absorbance at 405 nm of each well
was recorded using an ELISA reader against a PBS-coated well used as a blank. Wells
coated with BSA served as a control for nonspecific binding. Binding properties were
calculated and plotted as a function of the dose of protein rCBD.
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Construction of DNA vaccines
Cloning of the wapA and agA genes into the eukaryotic expression vector
pcDNA3.1/V5/His-TOPO
The wapA and agA were obtained by PCR amplification of a previously
constructed (145) plasmid pGEX-6P-GST containing wapA-E and wapA-G gene
encoding WapA and AgA, respectively, using the following two sets of primers:
wapA:
Forward: 5’-ACC ATG GAC CAA GTC ACA AAT TAT ACA-3’
Reverse: 5’-TTA TTA GCA TTA TTA TCA ATG TTA-3’
agA:
Forward: 5′-ACC ATG GAC CAA GTC ACA AAT TAT ACA-3′
Reverse: 5′ -TTA GTA GCC TGT TTG ATT GGA-3′
The initiation codon ATG was included in each forward primer to ensure
expression in eukaryotic cells. The PCR was performed as described below. The Kozak
consensus sequence ANNATGG was also inserted into wapA or agA forward primer to
increase the expression level of the genes. The plasmid used for cloning was engineered
to contain the pUC origin for replication and an ampicillin resistance gene for
propagation in the E. coli cells.
To obtain the expression of the cloned gene in mammalian cells the plasmid was
constructed so that the cloned gene was under the control of a strong viral promoter,
while the stability of the mRNA was provided by sequences downstream from the
polylinker consisting of a polyadenylation signal and transcription termination sequences
from the bovine growth hormone gene. The PCR products (Fig. 4) were ligated
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separately to pcDNA3.1/V5/His-TOPO employing the human cytomegalovirus (CMV)
immediate-early promoter/enhancer (Fig. 5).
The resulting DNA constructs were transferred into E. coli Top 10 cells by the
heat shock method as described by the manufacturer (Invitrogen). The transformed cells
were plated on LB agar containing ampicillin, and the resultant colonies were cultured
and screened by plasmid DNA isolation, followed by digestion with BstXI and analysis
by agarose gel electrophoresis. The PCR amplification, using vector sequence as a
forward or a reverse primer (specific to the T7 sequence or BGH Reverse primer site,
respectively), and the insert sequence (forward or reverse primer listed above), was
performed to test the correct orientation of the cloned gene in relation to the vector.
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FIGURE. 4. PCR-generated wapA-E and wapA-G genes. The wapA was amplified by
PCR. The location of the terminal amino acid positions and the letter designation of the
corresponding constructs are indicated.
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FIGURE. 5. Map of pcDNA3.1/V5-His-TOPO with wapA insert. The wapA-E and
wapA-G were inserted into this vector at the TA cloning site and transformed into E. coli
Top10.

PCR
PCR was performed for each sample with a 50-µl reaction mixture containing 1.5
mM MgCl2, 0.125 mM dNTP mixture, 1 U of Taq DNA polymerase, 50 pmol of each
primer, and 100 ng of template DNA. The PCR reaction was carried out in a gene cycler
(Bio-Rad, Hercules, CA) programmed for an initial denaturation step of 3 min at 95°C
and 30 cycles each of 30 s at 95 °C, 45 s at 54 C, and 1 min at 72 °C, with a final
extension of 10 min at 72 °C. The PCR products were visualized on 1% low melting
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point agarose gel containing ethidium bromide.
DNA sequencing
After construction, the plasmids were subjected to sequencing. Plasmids were
purified to sequencing grade using the alkaline lysis method described below and
sequences were determined by DNA sequence analysis conducted at the DNA
sequencing core facility of the H. Lee Moffitt Cancer Center & Research Institute
(Tampa, FL). The primer sets for sequencing were T7 forward primer: 5′-TAA TAC
GAC TCA CTA TAG GG-3′, and BGH Reverse primer: 5′-TAG AAG GCA CAG TCG
AGG-3′.
Optimization of wapA and agA DNA vaccine production and quality control
Chloramphenicol Amplification of Plasmid DNA containing agA
Observation of overnight cultures of the recombinant E. coli indicated a striking
difference in plasmid yield between clones harboring the wapA and agA DNA construct,
agA clones being much less productive for plasmid isolation. Clones with the agA
plasmid construct had the tendency to lyse, therefore decreasing overall plasmid
production. To increase the yield of GST-AgA plasmid, chloramphenicol amplification
of E. coli derived plasmids was used. 250 ml culture of LB medium containing 100
µg/ml ampicillin was grown and when the culture reached an O.D. of 0.4 at 600 nm,
chloramphenicol was added to a final concentration of 170 mg/L and incubated further
for 12 to 16 h at 37 °C with vigorous shaking. Plasmid production from a 250 ml culture
without chloramphenicol treatment was performed in parallel with the above condition
for comparison.
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Purification of DNA vaccine
Plasmid DNA was isolated from E. coli TOP-10 containing pcDNA-wapA or
pcDNA-agA by a modified alkaline lysis method using the Qiagen HiSpeedTM Plasmid
Maxi Kit (Valencia, CA) and following the manufacturer’s instruction. Briefly,
transformed E. coli TOP-10 was grown in batches of a 250 mL LB medium containing
100 µg/ml ampicillin. Following overnight (16 h) incubation at 37 oC, cells were
collected by centrifugation at 6,000 x g for 15 min at 4 oC. The cells were resuspended
with the resuspension buffer containing 50 mM Tris.Cl (pH 8.0), 10 mM EDTA, and 100
ug/ml RNase A and were followed by lysis with the cell lysis buffer containing of 200
mM NaOH and 1% SDS (w/v) for 5 min at room temperature.
After neutralization using the neutralization buffer (3.0 M potassium acetate, pH
5.5), the lysate was filtered and washed with wash buffer containing 1.0 M NaCl, 50 mM
MOPS, 15% isopropanol (v/v). Plasmid DNA from the filtered lysate was then purified
using a pre-equilibrated HiSpeed Tip and eluted in the elution buffer containing 1.0 M
NaCl, 50 mM MOPS, 15% isopropanol (v/v). Plasmid DNA was concentrated and
desalted by isopropanol precipitation and eluted in TE buffer. Purity and concentration
of DNA was determined by optical density (OD) reading in UV spectrophotometer at 260
and 280 nm. DNA measured larger than 1.7 in the ratio of OD260/OD280 was used in
this study. 1 OD is equal to 50 µg/mL of DNA.
Plasmid DNA preparation for immunization study
Plasmid in TE solution was then concentrated by precipitation with 0.7 volume of
isopropanol in the presence of 1:10 volume of 3 M Na Acetate (pH 3.0). The DNA was
collected by centrifugation at 17,210 g in SS-34 rotor for 10 min at 4 °C, washed with
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70% ethanol, and centrifuged again for 10 min. The pellet was dried and resuspended in
sterile PBS to reach a concentration of 2 mg/ml. DNA purity was assessed
spectrophotometrically and the ratio of OD260nm /OD280nm was calculated. DNA
preparation with a minimum absorbance ratio of 1.7 was used in the present study. For
quality control, DNA vaccine constructs were confirmed by BstXI digestions and agarose
gel electrophoresis, and by DNA sequence analysis conducted at the DNA sequencing
Core Facility of the H. Lee Moffitt Cancer Center & Research Institute (Tampa, FL).
Expression of S. mutans Wall-associated Protein A Gene in Chinese Hamster Ovary
Cells
Cell culture
Chinese hamster ovary (CHO) cells were obtained from M. Kimble (Department
of Biology, University of South Florida, Tampa, FL). The CHO cells were cultured in
DMEM supplemented with 10% FBS, 200 mM L-glutamine, 100 mM sodium pyruvate,
and antibiotics/antimycotic (penicillin 0.5 mg/ml, streptomycin 1 mg/ml, and 0.25 mg of
amphotericin B/ml of 0.85% saline) at 37°C in 5% CO2. The E. coli Top 10 cells were
cultured in Luria-Bertani (LB) broth or on an LB plate containing 1.5% agar. Ampicillin
was added at 10 µg/ml for the culture of recombinant E. coli.
Plasmids
A gene encoding WapA or AgA was isolated from the plasmid pGEX-6P-GST
containing wapA-E or wapA-G, respectively, and cloned into the mammalian expression
vector pcDNA3.1/V5/His-TOPO as described previously. For isolation and purification
of plasmid DNA, Qiagen HiSpeedTM Plasmid Maxi Kit (Valencia, CA) was used.
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Propagation and isolation of Plasmid DNA vector pcDNA3.1/V5-His TOPO
Propagation of the vector pcDNA3.1/V5-His-TOPO was carried out by
transformation of E. coli TOP10 using the heat shock method. When the 50 µl frozen
competent cells were just beginning to thaw, 100 ng plasmid DNA was added and
incubated on ice for 30 min. The cells were heatshock treated by placing them in a 37 °C
water bath for 1 min and then returned to ice. After 2 to 3 min on ice, 650 µl LB medium
was added and the cells were incubated at 37 °C for 1 h in a shaker at 15 rpm. Then, 25
to 100 µl of the suspension were aliquoted into the middle of an LB agar plate containing
100 µg/ml ampicillin and evenly spread over the plate using a spreader. The plates were
incubated at 37 °C overnight. The inserted plasmid DNA vector was isolated by a
modified alkaline lysis method as described above.
Transfection of CHO cells
Transient transfection was performed using the cationic lipid pfx-8 according to
the manufacturer (Invitrogen). Briefly, CHO cells were seeded in a 12-well microtiter
plate at a density of 5 X 104/well and incubated overnight to approximately 50%
confluency. The cells were washed by aspiration with sterile PBS, and a transfection
solution (1 µg of DNA mixed with lipid solution at a 1:6 ratio [v:v]) was added (1.0 ml
per well). After 4 h of incubation, the transfection solution was aspirated and replaced
with an equal volume of complete medium, and the incubation was continued for another
24 h. On the following day, the cells were detached by scraping, and the cell suspension
was collected.
Adsorption of antiserum
To avoid nonspecific binding of the antiserum to CHO cells, the antiserum was
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incubated for 1 h at room temperature and then overnight at 4°C with a piece of
nitrocellulose filter on which CHO cells were immobilized, and the free surface was
blocked with 10% skim milk in PBS. The nonbinding fraction was tested by a dot
immunobinding assay.
Dot immunobinding assay
To investigate the expression of wapA and agA in transfected CHO cells, a sonic
extract (prepared as described below) of each sample was dotted (10 µl per dot) onto a
piece of nitrocellulose membrane, which was next blocked by incubation with 10% heatinactivated horse serum in PBS. The filter was incubated for 1 h with the adsorbed rabbit
anti-S. mutans cell wall (1:200 dilution in PBS), followed by extensive washing in PBS
containing Tween 20 added at 0.05% (PBS-T) and a 1-h incubation with a horseradish
peroxidase-conjugated goat anti-rabbit immunoglobulin diluted 1:1000 in PBS.
Following an extensive wash in PBS-T, the peroxidase activity was identified using a
chemiluminescent substrate (ECL for HRP from Pharmacia). A piece of X-ray film
(Kodak) was next exposed to the filter for 1 min and developed in a Kodak M35A XOMAT processor.
Western immunoblot analysis of transfected CHO cells
Expression of WapA and AgA in transfected CHO cells was investigated by
Western blot analysis as follows. A sonic extract of the transfected CHO cells was
prepared using two pulses of 30 sec each in a Vibra CellTM (Sonics & Materials, Inc.,
Danbury, CT) set at 50 Hz. As controls, untransfected CHO cells and cells treated with
the lipid alone were similarly processed. The sonic extract was incubated with the
cracking buffer (0.019 M Tris, 0.5% SDS, 0.35 M 2-mercaptoethanol, 7.5% glycerol,
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0.05% bromophenol blue) for 3 min in a boiling water bath. The particulate was
sedimented by a 15-sec centrifugation at 6000 rpm, and the supernatant liquid from each
sample was separated by electrophoresis in a 10% SDS-polyacrylamide gel. The protein
bands were electrophoretically transferred to a piece of nitrocellulose membrane, which
was then blocked by incubation with 10% horse serum in PBS for 1 h at room
temperature. The membrane was processed for immunochemical staining as described
above for dot immunobinding assay.
Immunochemical staining of transfected CHO cells
A 100-µl sample of each cell suspension was transferred to a microscope slide, let
dry, and fixed with ice-cold acetone. The slide was next blocked with 10% nonfat dry
milk for 1 h at room temperature with gentle rocking. The cells were incubated at room
temperature for 1 h with a rabbit anti-S. mutans cell wall diluted 1:200 in PBS. The slide
was next incubated with PBS containing 10 mM EDTA to inactivate endogenous alkaline
phosphatase, as described by Dao (21), gently washed three times with PBS-T, then
immediately incubated for 1 h with an alkaline phosphate-conjugated goat anti-rabbit
immunoglobulin diluted 1:30,000 in PBS. After incubation, the slide was washed three
times with PBS-T and stained with a Fast Red RC solution prepared as described by
Sigma. After color development, the slide was rinsed three times with deionized water,
observed on the light microscope, and photographed using an Olympus digital camera
Model 3030Z (Olympus America Inc, Melville, NY).
Differential immunogenicity of a DNA vaccine containing the S. mutans wallassociated protein A gene versus that containing a truncated derivative antigen A
lacking in the hydrophobic carboxyterminal terminal region
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Animals
Six-to-eight-week-old female Balb/c mice were purchased from the National
Cancer Institute (Frederick, MD), and maintained in the controlled animal facilities of the
University of South Florida Medical School. All protocols using mice were approved by
the Institutional Animal Care and Use Committee at the University of South Florida.
The University program and facilities for animal care and use are fully accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care International
(AAALAC).
Bacterial strains and cell line
E. coli TOP10 cell (Invitrogen, Carlsbad, CA) clones harboring pcDNA-wapA or
pcDNA-agA were prepared in a previous study as described above. The recombinant E.
coli strain BL21 (DE3) transformed with the expression plasmid pGEX 6.1 Glutathione
S-Transferase (GST), containing wapA or agA gene and expressing WapA or AgA as a
GST fusion protein, were prepared previously and used in the present study as a source of
recombinant antigens. HeLa cells were obtained from American Type Culture Collection
(ATCC) (Manassas, VA) for use in in vitro transfection experiments.
DNA Vaccine
The eukaryotic expression vector pcDNA3.1/V5-His-TOPO (Invitrogen,
Carlsbad, CA) containing the full length wapA gene (previously wapA-E) or truncated
agA gene (previously wapA-G), encoding WapA and AgA, respectively, were cloned
into the E.coli TOP 10 in a previous study and are referred to in the present report as
pcDNA-wapA and pcDNA-agA vaccine, respectively.
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Transfection of pcDNA-wapA in HeLa cells
To determine the optimal transfection conditions, HeLa cells were transfected
with pcDNA3.1/V5-His-TOPO containing the β-galactosidase gene (pcDNA-β-gal)
mixed with the cationic lipid DMRIE-C at various ratios. Briefly, HeLa cell cultures
were seeded with 5 x 104 cells in a 24-well microtiter plate and grown overnight at 37 °C
in a CO2 incubator until approximately 80% confluence. The cells were washed in a
serum-free medium and incubated with a transfection solution consisting of 2 µg of
pcDNA-β-gal mixed with 2-24 µg of DMRIE-C in a serum-free medium. After 4 h of
incubation, a growth medium containing 20% fetal bovine serum (FBS) was added, and
the incubation was continued for another 24 h. On the following day, the cells were
solubilized with M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, IL),
and centrifuged, and the cell suspension was collected for β-galactosidase assay. 50 µl of
cell lysate was added into the 96-well plate, mixed with 50 µl of 2X Assay Buffer
(Promega, Madison, WI) that contained the substrate ONPG (O-nitrophenyl-β-Dgalactopyranoside). β-galactosidase activity was measured at 420 nm with a
spectrophotometer..
Immunization of mice by the intranasal inhalation technique
To investigate the diffusion of 100 µl of vaccine solution when administered by
the intra-nasal drop technique, 100µl of sterile PBS containing 1/10 volume India ink
were delivered slowly as droplets at the opening of the nostrils of the non-anaesthetized
mouse held tightly by hand. Hand pressure was applied to the lower mandible of the
mouse in order to reduce swallowing of the instilled material during administration. This
procedure was performed on four mice, which were then sacrificed immediately and 30
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min later. The mice tissues including nasal and oral cavities, lung tissue, esophagus, and
trachea were inspected for any trace of the India ink as an indicator of vaccine diffusion.
Immunization of mice
Female BALB/c mice were distributed into five groups of three each and were
immunized intra-nasally with one of the following: 50 µg pcDNA-wapA (Group 1) or
pcDNA-agA (Group 2) combined with 150 µg of the cationic liposome carrier DMRIE-C
(1:3, w/w). The negative control mice were not immunized (Group 3) or administered
with empty plasmid vector mixed with DMRIE-C at the same ratio (Group 4), or with
PBS mixed with DMRIE-C (Group 5). Two doses were administered at three-week
intervals.
Collection of saliva and blood samples
Saliva and blood samples were collected prior to immunization, and 3 and 6
weeks after boost immunization. Briefly, saliva samples were collected after intraperitoneal injection of 100 µl of 1 mg/ml pilocarpine (Sigma, St. Louis, MO) in PBS to
stimulate saliva secretion. Saliva was immediately centrifuged at 735 g for 30 min. The
supernatant was collected, the protease inhibitor Phenylmethyl sulfonyl fluoride (PMSF,
100 mM) was added at 1% (v/v), and the sample was stored at –20 °C until use. Blood
was collected from the tail vein, allowed to clot at room temperature for 1 h and stored 30
min at 4 °C. Serum was then separated from the clot by centrifugation at 3,210 g for 30
min and stored at –20 °C. Saliva samples from the mice in each group were pooled for
analysis. Serum samples were collected and tested individually.
Dot immunobinding assay
To investigate the presence of specific IgA in the saliva of the immunized mice, a
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piece of 96 well-embossed nitrocellulose membrane was dotted with 10 µl per dot of 5
µg/ml of purified GST-AgA fusion protein and allowed to dry at room temperature.
After 10 min of incubation in the cold, the filter was blocked by incubation with PBS
containing 2% Tween 20, at room temperature for 1 h. Next, small NTC pieces
containing antigen dots were cut out and incubated individually overnight at 4 °C with
the diluted (1:2) saliva samples to be tested. The pieces of NTC were washed six times
with in PBS-T, and then incubated for 1 h with a HRP-conjugated goat anti-mouse IgA
diluted to 1:10,000. After a final wash in PBS-T, the membrane was incubated with a
HRP chemiluminescent substrate (obtained from Amersham Pharmacia Biotech,
Piscataway, NJ) for 1 min and exposed to an X-ray film (Kodak) for development.
Enzyme linked immunosorbent assay (ELISA)
Saliva and serum samples were assayed for anti-WapA salivary sIgA and serum
IgG using enzyme-linked immunosorbent assay (ELISA). The purified GST-AgA fusion
protein was used as the coating antigen (146). Immunolon IV 96-well microtiter plates
(Dynex, Chantilly, VA) were coated overnight at 4 °C with 100 µl per well of 5 µg/ml
solution of antigen in coating buffer (50 mM carbonate/bicarbonate buffer, pH 9.6). The
wells were blocked with 200 µl of 10% skim milk in PBS for 1 h and washed four times
with PBS containing 0.05% Tween 20 (PBS-T). Saliva was diluted 1:2 and serum at 1:16
in PBS, each sample was added in serial 2-fold dilution to the wells, and the plate was
incubated at 4 °C overnight. After three washes with PBS-T, 100 µl of horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgA diluted to 1:1,000 in PBS-T was used.
The plates were incubated for 1 h at room temperature. Following extensive washes in
PBS-T, 100 µl of QuantaBlue Fluorogenic peroxidase substrate (Pierce, Rockford, IL)
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was added to each well and incubated for 30 minutes at room temperature. Peroxidase
activity was detected on the fluorometer by reading the excitation and emission at 325 nm
and 420 nm, respectively. The end point titers antigen-specific IgG and IgA were
determined in triplicate and expressed as the reciprocal of the highest dilution giving an
OD corresponding to 3 X the standard deviation above the mean of the background
control sample.
Assay of antibodies to recombinant AgA
Pooled saliva from each group of mice was extensively absorbed with E. coli BL
21 homogenate immobilized on nitrocellulose in order to remove unwanted antibodies.
The E. coli recombinant clone expressing AgA and the negative control E. coli
transformed with the vector pGEX-6P-1 alone were sonicated and centrifuged at 12,000 x
g for 30 min. The soluble fraction was loaded in triplicate lanes (2 µg/line) and separated
by SDS-PAGE followed by electro-transfer of the protein bands onto a piece of
nitrocellulose. The protein bands were incubated with purified anti-WapA or –AgA
antibodies and subsequent steps were as described previously for the dot immunobinding
assay.
Assay of antibodies to S. mutans WapA
Cultures of S. mutans were grown in BHI supplemented with 2% sucrose for 16 h
at 37 °C. Cultures were sonicated and an equal volume of sonic extract was loaded in 4
sets of duplicate lanes (2 µg/lane). SDS-PAGE separated protein bands were transferred
to 0.2 µm nitrocellulose membrane at 100V for 1 h. Differential immunoreactivity of
anti-WapA or –AgA antibodies to WapA was tested by incubating the membranes with
each antiserum and following steps for the Western blot analysis as described above.
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In vitro Adherence inhibition assay
The influence of salivary IgA on the sucrose-dependent adherence of S. mutans
GS-5 was assayed in vitro and quantified as described by Olson et al. (94) with some
modifications. At 6 weeks post-booster immunization, saliva samples collected from
immunized or control mice, and the antigen-specific sIgA level was measured using
ELISA. Saliva samples with equivalent levels of specific sIgA were sterilized by mixing
with 1/10 volume of chloroform and the aqueous layer, separated by centrifugation for 2
min at 16,000 g, was diluted to 1:2 in PBS. 200 µl of saliva diluted in PBS was added
into 24 well cell culture plates containing 200 µl of BHI medium prepared at two times
the standard concentration and supplemented with 2% filter-sterilized (Millipore Corp.;
0.45 µm pore size) sucrose.
A saturated overnight culture of S. mutans was diluted to 1:100 in BHI medium
and 10 µl of the diluted suspension was added into each well. Binding assay was carried
out by incubation of the plate at 37 °C for 20 h. Saliva samples from pre-immunized or
non-immunized mice were used as controls, and assayed as described above for the test
samples. After incubation, non-adherent S. mutans were removed by aspiration of the
medium, and the wells were washed three times with 0.5 ml of 0.9% saline. The washes
were pooled.
For quantitative analysis, the bacteria were detached from the wells by washing
four times with 0.5 ml volumes of 0.5 N NaOH, and the washes were pooled. S. mutans
were collected from the washes by centrifugation at 6,000 g for 1 min, the supernatant
was discarded, and the cell pellet was resuspended with 400 µl of 0.5 N sodium
hydroxide. The optical density (OD) of the suspensions was measured at a wavelength of
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540 nm and the mean adherence level was determined and expressed as percent OD of
the total cells (non-adherent cells in the culture medium plus adherent cells detached
from the well by NaOH).
Dextran binding Assay
Dextran-binding properties were investigated for GST-WapA or GST-AgA fusion
proteins using a Biotin-conjugated dextran (Sigma, St. Louis, MO) by dot
immunobinding assay as follows. GST-WapA and GST-AgA fusion proteins were
obtained from the corresponding recombinant E. coli BL 21 after induction with IPTG
and the recombinant proteins purified by chromatopgraphy on a glutathione-conjugated
Sepharose column following the manufacturer protocol (Amersham, Piscataway, NJ).
Next, 10 µl of 5 µg/ml of the purified protein was dotted onto a piece of 96 wellembossed nitrocellulose membrane and processed as described above for the dot
immunobinding assay. The membrane was incubated with biotin-conjugated dextran for
1 h at room temperature, and the dextran-binding protein was identified by incubation
with AP-Streptavidin solution at room temperature for one hour, followed by in situ
staining of AP activity (21).
Statistical analysis
Data for serum or saliva antibody titers were logarithmically transformed and
statistical differences were determined by using the nonparametric Mann–Whitney U-test.
Data obtained from the adherence inhibition assay were also analyzed with the
nonparametric Mann–Whitney U-test for the difference in the median values among the
groups.
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Efficacy of DNA versus Protein Vaccine: Relative induction of mucosal IgA
response to S. mutans Wall Associated Protein A
Experimental animals
Balb/c female mice, 6-8 weeks old, were purchased from Charles River
Laboratories (Wilmington, MA) and were maintained in the animal facilities of the USF
medical school.
Cell lines
HeLa cells were purchased from ATCC (Manassas, VA) and maintained in
Dulbecco-modified Eagle medium supplemented with 10% fetal calf serum at 37 °C in
5% CO2.
Bacterial strains, plasmids, and media
The three clones needed for this study were obtained previously and included the
following: Clone 1 consisted of recombinant E. coli TOP10 clone containing the wapA
gene cloned into the mammalian expression vector pcDNA3.1/V5/His-TOPO. The
clones were used to propagate the plasmid containing wapA-pDNA. The DNA plasmid,
namely pcDNA-wapA which encodes the S. mutans WapA, was described previously.
Clones 2 and 3 consisted of recombinant E. coli BL21 containing the wapA gene or agA
gene cloned into the prokaryotic high expression fusion vector pGEX 6-1 GST. These
clones, designated BL21-WapA and BL21-AgA, expressed the WapA and AgA,
respectively, as a fusion protein with GST. The WapA or AgA expression plasmid,
designated GST-WapA or –AgA, respectively, was also described previously.
Cloning of murine IL-5 cytokine gene into the mammalian expression vector
To investigate the effect of IL-5 on salivary IgA production in the immunized
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mice, recombinant E. coli HB101 containing IL-5 cDNA cloned into vector pBR322 was
obtained from ATCC. PCR amplification was performed using primers for IL-5, which
was designed based on the IL-5 DNA sequence found in Genebank (Accession No.
NM_010558). The primers used were as follows: Forward, 5′-ACC ATG AGA AGG
ATG CTT CTG CAC-3′ and Reverse, 5′-TCA GCC TTC CAT TGC CCA-3′ The
resulting fragment of 402 bp was cloned downstream of the CMV promoter into
pcDNA3.1 vector. PCR and cloning protocols used were described previously.
Cloning of the cholera toxin B-subunit (ctb) gene into the mammalian expression vector
The ctb plasmid construct was prepared by cloning a ctb gene into the mammalian
expression vector pcDNA3.1/V5/His-TOPO according to the protocol above. Genomic
DNA of Vibrio cholera was obtained from ATCC. Since the ctb gene sequence was
known (GenBank accession no. D30053), the genomic DNA obtained was used as a
template for the amplication of the CTB gene by PCR using specific primers. The
primers used were; Forward, 5′-ACC ATG ACA CCT CAA AAT ATT ACT GAT T-3′
and Reverse, 5′-TTA ATT TGC CAT ACT AAT TGC GG-3′.

Cloning of the ctb gene into a pGEX expression vector
The ctb gene was cloned into prokaryotic high expression pGEX-6P-1 glutathione
S-transferase (GST) fusion vector using the manufacturer protocol (Pharmacia). PCR
primers derived from the ctb gene sequence in GenBank (accession no. D30053) was
used to amplify the ctb gene without signal peptide and was subcloned into the TA
cloning vector pCR2.1-TOPO (Fig. 6) The ctb gene digested with EcoRI was ligated in
frame with GST-tag into the pGEX GST fusion vector (Fig. 7). The E. coli BL21
competent cells were transformed with the ligation mixtures, the transformant containing
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pGEX-ctb was grown at 37 °C, and expression was induced with 1mM IPTG as
described previously. After induction, cells were lysed by sonication and were purified
by the Glutathione Sepharose 4B protocol. The purity and identity of the protein was
confirmed by 10% SDS-PAGE followed by Western blot analysis.

FIG. 6. Map of pCR2.1-TOPO plasmid vector. ctb gene was cloned into pCR2.1-TOPO.
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FIG. 7. Map of prokaryotic expression vector pGEX-6p-1. The pCR2.1-TOPO clone
containing ctb gene was excised and subsequently cloned via the EcoR1 restriction
enzyme site into pGEX-6p-1 plasmid from which proteins can be expressed as fusion
proteins with glutathione S-transferase (GST).

DNA sequencing
After construction, the plasmids were sequenced to confirm the orientation and
sequence. Plasmids were purified to sequencing grade using the alkaline lysis method
described below and Sequences were determined by DNA sequence analysis conducted
at the DNA sequencing core facility of the H. Lee Moffitt Cancer Center & Research
Institute (Tampa, FL). The primer sets for sequencing were T7 forward primer: 5′-TAA
TAC GAC TCA CTA TAG GG-3′ and BGH Reverse primer: 5′-TAG AAG GCA CAG
TCG AGG-3′.

44

Expression and Purification of WapA and AgA from E. coli recombinant clones
To obtain enough proteins for the immunization study and for the preparation of
rabbit antibodies, isolation of these proteins was scaled up. Both WapA and AgA were
obtained from the corresponding recombinant E. coli BL21 (DE3) clones. The clones
expressing GST-WapA and GST-AgA were cultured at 37 °C in an incubator shaker
overnight in batches of 500 ml 2x YTA medium containing 100 µg/ml ampicillin. The
following day, the overnight culture was diluted 1:100 into fresh pre-warmed 2x YTA
medium, and incubation was continued at 37 °C until the A600 reached about 1. Induction
of protein expression and preparation of the protein lysate was followed in the same
manner as described above.
The protein lysate was incubated on a rocker for 30 min at room temperature,
after 0.5 ml of glutathione-linked Sepharose 4B (Pharmacia) in a 50% slurry was added.
The mixture was transferred onto a chromatographic column, and washed by adding 50
ml of PBS/1 mM PMSF. The fusion protein was eluted by 10 mM reduced glutatione in
five aliquots of 300 µl each. Cleavage of GST tag was carried out by incubation with
PreScission protease as described previously. The quantity of the AgA was determined
by OD reading at 280 nm. 1 OD280 equals 0.5 mg/ml, the formula based on the extinction
coefficient of free GST. The purity and solubility of the AgA was analyzed by SDSPAGE.
The amount of recombinant proteins without GST tags was determined by the
bincinchonic acid method using reagents and protocols obtained from Sigma. Briefly,
0.1 ml of the sample was mixed with 2 ml of protein determination reagent (1 part
Copper sulfate pentahydrate 4% solution added to 50 parts of Bicinchonic acid solution).
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The mixture was mixed by vortex followed by incubation at 37 °C for 30 min. After
cooling of the tube to room temperature, the absorbance was recorded at 562 nm, and the
concentration of protein determined from a standard curve established with solutions of
bovine serum albumin (20, 40, 60, 80, 100 µg/ml) assayed in parallel.
Measurement of GST Activity by CDNB Assay
Rapid enzymatic detection assay using the GST substrate 1-chloro-2,4dinitrobenzene (CDNB) was used to optimize conditions for expression or to quantify the
level of expression of GST fusion protein. High affinity between the GST and 1-chloro2,4-dinitrobenzene (CDNB) resulted in a CDNB-glutathione with a strong absorbance at
340 nm. When a sample containing a GST fusion protein was incubated in a CDNB
assay solution containing CDNB and glutathione, the relative or absolute amount of GST
fusion protein in the sample could be calculated by comparing a standard curve of
A340/min versus fusion protein amount. Briefly, the total volume of 1000 µl CDNB assay
solution (100 mM CDNB, 100 mM reduced glutatione, 10X reaction buffer and distilled
waterl) was mixed and transferred into two UV-transparent cuvettes with 500 ml volume
each.
The soluble (post-sonicate) fraction of the fusion protein or the GST-WapA
purified soluble protein was added into the sample cuvette to be assayed. To the other
cuvette (blank cuvette), a volume of 1X reaction buffer in an amount equal to the sample
was added. Measurements were conducted at 340 nm in a UV spectrophotomer at oneminute intervals for 5 minutes. Blanking the spectrophotometer with the blank cuvette
was done before each reading of the sample cuvette. Recorded absorbance readings were
used to calculate A340/min/ml values which could be used as a relative comparison of
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GST fusion protein content between samples.
Production of protein vaccines and DNA vaccines against S. mutans WapA and AgA
The plasmid DNA containing wapA or agA gene and the corresponding
recombinant WapA and AgA were isolated and an average yield was calculated as a
function of culture volume for comparison. Plasmid DNA containing wapA or agA was
prepared from E. coli TOP-10 by a modified alkaline lysis method using a Qiagen
HiSpeedTM Plasmid Maxi Kit (Valencia, CA), as described previously. The goal was to
optimize the isolation of these antigens as recombinant proteins or as genes separately
inserted into a eukaryotic expression plasmid vector, and to compare the yield between
the two target antigens. The purified recombinant protein and DNA vaccines were used
in the immunization study.
Immunogenicity of the fusion proteins
Considering that fusion proteins can elicit a strong and specific antibody response
to the target antigens, it is hypothesized that the presence of GST did not interfere with
the immunogenicity of the target protein. Indeed, the antigenicity of WapA-GST and
AgA-GST was demonstrated by immunodot analysis using a rabbit antibody to the wild
type WapA and AgA. Considering the advantage of skipping the cleavage of GST from
the fusion proteins in term of time and money, this step was omitted from our production
of protein vaccines.
Preparation of rabbit polyclonal antibody against WapA
Rabbit polyclonal antibody against WapA was prepared for the identification and
immunochemical analysis of WapA and AgA in the present study. Briefly, six 4 kg
female albino rabbits from the New Zealand strains were immunized intramuscularly
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with 100 µl of 1mg/ml of WapA mixed with TiterMax Gold (Sigma) adjuvant Freund
complete adjuvant (v:v). Booster injections were administered with WapA or AgA mixed
with the TiterMax Gold adjuvant (v:v) at three-week intervals. Blood was collected before
immunization and one week after each booster injection.
The serum was separated by centrifugation and decomplemented by heating at 55 oC
in a water bath for 30 min. The serum was sterilized by adding 1/10 vol of chloroform,
mixing, and centrifugation to obtain the aqueous upper layer containing the antibody. Dot
immunobinding assay and ELISA were performed to test the serum for the presence of a
specific IgG antibody, as described previously. Larger volumes of blood were obtained
when a dilution of the antibody at 1:500 in PBS gave a positive reaction in immunodot
analysis.
Absorption of anti-E. coli and anti-GST antibody from rabbit serum
Nonspecific binding of the antiserum to WapA was removed by extensive
absorption of serum against E. coli and GST. Anti-E. coli absorption was completed as
described previously. For the absorption of anti-GST antibodies, Glutathione Sepharose
4B attached with GST was packed onto a gravity-flow column. Serum was loaded on a
column and incubated for 1 h at room temperature. Incubation was continued for 1 h at 4
C, and the absorbed serum flow-through was collected. Fractions were tested for
antibody activity using dot immunobinding assay (Fig. 8).
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FIG. 8. Absorption of immune serum. To remove non-specific binding of antiserum to
WapA, anti-E. coli and –GST activity was absorbed from serum against sonicated E. coli
fraction and purified GST dotted on a nitrocellular membrane. A1 (anti-WapA), A2
(anti-GST) or A3 (anti-E. coli) shows its antibody activity reacting on purified GSTWapA, GST, or E. coli fraction, respectively, before absorption. B1, B2, and B3 are
corresponding antibody activity after absorption.

Purification of IgG antibody against WapA
WapA or AgA specific antibodies from post-immune rabbit serum were purified
using the Melon™ Gel IgG Purification Kit, by the procedure specified by the
manufacturer. Serum was diluted by 1:10 with melon gel purification buffer and loaded
on a gravity-flow column. The specific antibodies were eluted with Melon Gel
Purification Buffer, and the absorbance of the antibody fractions were measured at 280
nm.
Induction of WapA in presence of sucrose
Cultures of S. mutans were grown in BHI or BHI supplemented with 2% sucrose
for 16 h at 37 °C. Cultures were sonicated and an equal volume of sonic extract was
loaded in 4 sets of duplicate lanes (2 µg/lane). SDS-PAGE separated protein bands were
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transferred to 0.2 µm nitrocellulose membrane at 100V for 1 h. Expression of WapA in
the presence of sucrose was evaluated by probing membranes with anti-WapA antibodies.
Immunization protocols
The mice were divided into 3 groups as follows: Group 1 mice were intra-nasally
immunized with pcDNA-wapA alone, or with pcDNA-il-5 encoding IL-5 or with
pcDNA-ctb encoding the cholera toxin B subunit (CTB). Group 2 mice were immunized
with WapA and CTB. Group 3 mice were primed with pcDNA-wapA and boosted with
WapA.
Collection of saliva
Mice were injected by i.p. 100 µl pilocarpin (1 mg/ml) to induce salivary flow.
Saliva was collected by aspiration from the cheek pouch. Phenyl methyl sulfonyl
fluoride (PMSF) was added at 1mM as a protease inhibitor and the saliva was stored at 70 °C until use, at which time the sample was centrifuged and the supernatant used in
immunochemical assays.
Immunodot analysis
The presence of specific sIgA expressed in the saliva of immunized animals was
detected by immunodot analysis of the in situ staining for alkaline phosphatase. A purple
coloration was indicative of the presence of salivary sIgA against WapA. Saliva from
unimmunized mice served as negative controls.
Enzyme-linked immunosorbent assay
To follow the production of specific salivary IgA over time, ELISA was used to
determine the salivary IgA titre. Production of salivary IgA (mean titer from 6 animals
and standard deviation) was calculated and plotted as a function of time post-imunization.
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RESULTS
B cell epitope prediction of the WapA protein
Identification of B cell epitopes on the WapA was made using different
parameters for prediction of antigenic determinants, including hydrophilicity,
accessibility and flexibility, experimental antigenic determinant data, and
physicochemical properties of amino acids (Fig. 9). Consensus epitopes were identified
based on predicted epitopes and their frequency within different algorithms. Table 1
shows the consensus antigenic determinants in the WapA sequence, indicating 11
strongly antigenic sites within AgA and 4 sites around the membrane-spanning domain.
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FIG. 9. B cell epitope prediction by four algorithms; Hopp and Woods (A), Parker (B),
Welling (C), and Kolaskar and Tongaonkar algorithm (D). Values greater than 0 are
predicted antigenic sites and are likely to be exposed on the surface of a folded protein
(A, B, and C). Kolaskar and Tongaonkar algorithm (D) gives sites that ares potentially
antigenic a value above 1.0.
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TABLE 1. Consensus antigenic determinants within the WapA sequence.
n Start Position

Sequence

End Position

1

5

RKLLSLVSVLTILLGAFWVTKIVKA

29

2

53

PSKAVNYWEPLSF

65

3

71

FPDEVSI

77

4

83

LTIKLPEQLQFTT

95

5

119

GEVTVTF

125

6

152

SIPGVVN

158

7

161

YNNVAYSSYVKD

172

8

175

ITPISPDVNKVGY

187

9

192

NPGLIHWKVLI

202

10

213

TLTDVVG

219

11

222

QEIVKDSLVAARLQY

236

12

284

NAIFISYTT

292

13

401

TSKQVTK

407

14

409

KAKFVLP

415

15

420

QAGLLLTTVGLVIVAVAGVYF

440

Detection of MHC class II binding regions
The amino acid sequences of AgA and its larger precursor WapA were analyzed
using virtual matrices algorithms by which binding values were compared with 51 sets of
known MHC class II alleles. MHC Class II binding specificity was shown as the
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percentage of motif matches within the sets of 51 DRB alleles that cover more than 90%
of MHC Class II molecules expressed on antigen presenting cells. Analysis at a 3%
threshold identified 6 more promiscuous binding regions in WapA, but not in AgA (Fig.
10). One of these regions, beginning at residue 400 (Fig.10), showed the highest
promiscuous binding regions with over 90% promiscuousness for the predicted region of
peptide against 51 known MHC II alleles.
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FIG. 10. Detection of MHC-II promiscuous binding motifs in WapA. Motifs associated
with 51 MHC class II alleles (listed under the graph) were identified in the sequence of
WapA using a MHC class II binding motif-matching algorithm. Each peak represents
percent of promiscuousness for the predicted region of peptide against 51 known MHC II
alleles that cover more than 90% of MHC Class II molecules expressed on antigen
presenting cells. Six distinct regions beginning at residue 294, 300, 382, 388, 394, and
400 were identified which were within the WapA and not AgA.
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Identification of N- or O-glycosylation sites in WapA sequence
Asn-Xaa-Ser/Thr sequences were identified on WapA, and asparagines residues
predicted to be N-glycosylated were determined based on the potential value calculated
using the NetNGlyc server. Six sites were predicted to be N-glycosylated with high
specificity across the WapA sequence (Fig. 11). The O-glycosylated sites were
predominantly predicted to be in coil regions (Fig. 12).

FIG. 11. Prediction of N-glycosylation sites in WapA sequence. The X-axis represents
protein length from N- to C-terminal and the Y-axis the predicted N-glycosylation
potential at that position. Values above the threshold (horizontal line at 0.5) are predicted
to be N-glycosylated.
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FIG. 12. Predicted O-glycosylation sites in WapA sequence. The X-axis represents the
WapA sequence position in the multiple alignments and the Y-axis the predicted Oglycosylation potential at that position. A position with a potential (vertical lines)
crossing the threshold (dotted line) is regarded as O-glycosylated.

Glycosylation of the anti-WapA DNA vaccine candidates
The possibility of WapA or AgA glycosylation was considered in the process of
selecting the anti-S. mutans DNA vaccine candidates. Cloning of a series of truncations
of the wapA gene at the N-terminal and C-terminal ends into the expression vector
pGEX-6P-1 glutathione S-transferase (GST) fusion vector demonstrated that only
constructs GST-WapA-D, -E, -F, and –G, showed a strong cross-reaction with the
polyclonal WapA antibody raised in rabbit (146). Detailed descriptions of those inserts
are as follows:
wapA-D: 1335 b.p. fragment of wapA missing the promoter
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wapA-E: 1251 b.p. fragment of wapA missing the promoter and signal peptide
wapA-F: 968 b.p. fragment of wapA missing the promoter and wall spanning region.
wapA-G: 885 b.p. fragment of wapA missing promoter, signal peptide, and wallspanning region
The truncated wapA-E and wapA-G were selected to prevent target proteins from
being glycosylated in mammalian host cells for the source of DNA vaccine construction.
The wapA-E and wapA-G were truncated versions of wapA, both lacking in signal
peptide sequence, therefore preventing target proteins from being glycosylated in
mammalian host cells. In eukaryotic cells, proteins are synthesized in the cytoplasm or in
the endoplasmic reticulum. Protein glycosylation occurs in the RER, and RERsynthesized proteins are distinguished from those synthesized in the cytoplasm by the
presence of signal peptides (13-36 residues containing 7-13-residue hydrophobic core
flanked by several relatively hydrophilic residues usually with one or more basic residues
near the N-terminus). Similarly, bacterial membrane proteins are also preceded by signal
peptides such as in the case of WapA.
To avoid glycosylation of WapA, wapA-E, and wapA-G were selected, which
were truncated versions of the wapA gene that did not contain sequences encoding the S.
mutans signal peptide. Taken with the lack of a eukaryotic signal sequence in the cloning
vector, this meant that it was not likely that nascent protein synthesized in the cytoplasm
could be translocated to the RER for further elongation and glycosylation. Despite a
number of potential glycosylation sites with Thr and Ser residues in the wapA gene,
glycosylation was successfully prevented and antigenicity was conserved.
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Codon optimization
The ability of the vacinee to produce the protein encoded by the DNA vaccine is
often correlated with comparative codon usage between foreign and host genes. Analysis
of the S. mutans or WapA gene sequence showed the difference of the codon usage
frequencies compared to those prevalent in the human genome (Fig. 13 and 14). The
pattern of usage difference in the wapA position revealed 19 low-usage codons for
expression in mammalian systems (Fig. 15). In order to improve the heterologous
expression of wapA sequence in the mammalian system, the frequency of wapA and
human codon usage was determined, and optimized codons were suggested in Table 2.
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FIG. 13. Comparison of codon usage for each amino acid used by S. mutans and H.
sapiens genes. Mean difference of 26.7% was calculated between two species. S. mutans
codon was colored red. The black bar was used for H. sapiens codon usage.
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FIG. 14. Codon usage of wapA gene compared with the H. sapiens genes for each
amino acid. Mean difference of 24.89% was calculated between two species. Codon
fraction colored in red is wapA. H. sapiens was shown as the black bar.
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FIG. 15. Analysis of codon usage pattern of wapA to the common codon usage of H.
sapiens at each position of the gene. Red bar indicates low usage codon with less than
10% codon match to the codon usage of H. sapiens. Grey bar shows less than 20% of
codon usage match.
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Amino
Acid
Ala

Arg

Asn
Asp
Cys
Gln
Glu
Gly

His
Ile

Leu

Lys
Met
Phe
Pro

Ser

Thr

Trp
Tyr
Val

wapA
codons
GCA
GCC
GCG
GCT
AGA
AGG
CGA
CGC
CGG
CGT
AAC
AAT
GAC
GAT
TGC
TGT
CAA
CAG
GAA
GAG
GGA
GGC
GGG
GGT
CAC
CAT
ATA
ATC
ATT
CTA
CTC
CTG
CTT
TTA
TTG
AAA
AAG
ATG
TTC
TTT
CCA
CCC
CCG
CCT
AGC
AGT
TCA
TCC
TCG
TCT
ACA
ACC
ACG
ACT
TGG
TAC
TAT
GTA
GTC
GTG
GTT

Frequency
wapA codon
24
0
6
71
27
9
9
9
0
45
28
72
13
88
0
0
89
11
13
88
33
4
13
50
33
67
8
20
72
6
3
3
16
35
35
74
26
100
29
71
57
7
36
0
8
28
20
10
3
33
49
7
8
35
100
13
88
26
18
6
50

Human codon
Frequency
23
40
11
26
20
20
11
19
21
8
54
46
54
46
55
45
26
74
58
42
25
34
25
16
59
41
16
48
35
7
20
40
13
7
13
42
58
100
55
45
27
11
28
33
24
15
15
22
6
18
28
36
12
24
100
57
43
11
24
47
18

Optimized
codon

Human codon frequency
of the optimized codon

GCC

40

CGG

21

AAC

54

GAC

54

TGC

55

CAG
GAA

74
58

GGC

34

CAC

59

ATC

48

CTG

40

AAG
ATG
TTC

58
100
55

CCG

28

AGC

24

ACC

36

TGG
TAC

100
57

GTG

47

Table 2. Codon optimization of wapA gene. The codons and their frequency of
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occurrence in the WapA gene are compared with the codon frequencies of the most
common codon usage of the human gene. The codon-optimized WapA gene represents
the optimal codon for human codon usage.

Comparative sequence analysis of the putative collagen binding domain in WapA
Blasting the deduced amino acid sequence of WapA against the NCBI Conserved
Domain Database (CDD) revealed a significant hit (E = 9e-20) for the collagen binding
domain (Fig. 16A). Amino acids at position’ 150 to 286 of WapA were aligned 100%
with pfam05737 consensus residues of the collagen binding domain (Fig. 16B).
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FIG. 16. Alignment of deduced amino acid sequences of WapA with conserved domain
databases. (A) Domain organization of S. mutans WapA. Amino acids 150-286 (putative
CBD of WapA) were aligned 100% with 134 consensus residues of collagen binding
domain in NCBI Conserved Domain Database (CDD). WapA signal peptide (S),
proteolytic cleavage site (PC), cell wall domain containing LPSTG motif (W), and
membrane-spanning domain (M) are indicated. The shaded region denotes the putative
collagen binding domain (150-286) that was represented by CBD. The region of the
expressed recombinant protein (rCBD) used in this study is also shown. (B) Sequence
identity (E = 9e-20) to the collagen binding domain family was identified within the pfam
database (pfam05737), where 33.8% identity in 134 amino acids overlap.
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Structure analysis of putative collagen binding domain in WapA
Results of a secondary structure prediction algorithm using the 3D-PSSM
program suggested that the submitted portion of WapA was a collagen binding domain.
Prediction of secondary structure and its probable function as a collagen binding domain
was matched significantly with the polypeptide chain of the collagen binding domain of
the Cna protein from S. aureus with over a 95% confident hit (E = 1.68e-08) (Fig. 17).
The putative collagen binding domain also has a significant hit (E = 5.3e-22) with the
collagen-binding domain of S. aureus, from the result of sequence searches against
SCOPE, suggesting a common function and implying a probable common evolutionary
origin.
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FIG.17. The predicted secondary structure for the putative collagen binding domain in
WapA was generated using the 3D-PSSM program, and was aligned to the significant
structural match (E = 1.68e-08) of the fold library. The predicted secondary structure of
the putative collagen binding domain in WapA shares structure motifs showing similar
secondary structure topology with the assigned collagen binding domain of the Cna
protein from S. aureus. E is extended beta strand; C is coil; and H is alpha helix.

Expression of recombinant collagen binding domain
A WapA gene fragment encoding the predicted collagen-binding domain was
expressed in E. coli BL21 clone, and denoted rCBD. rCBD was purified and cleaved
from glutathione S-transferase with the PreScission protease. The purified protein
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representing the collagen binding domain of wapA was shown as a single band of
approximately 29 kDa in SDS-PAGE (Fig. 18).

FIG. 18. Expression and purification of recombinant collagen binding domain. Cterminal truncated wapA-G cloned into pGEX-6P-1 was expressed in E. coli BL21. The
resulting fusion proteins were purified on glutathione-Sepharose column followed by
cleavage of the GST tag with PreScission protease. The purity of rCBD was evaluated on
10% SDS-PAGE gels stained with Coomassie blue. All lanes showed column pool and
subsequent column passages.

Collagen Binding Properties of WapA
Immunodot analysis was used to detect the collagen binding properties of WapA,
which contained the putative collagen binding domain. As shown in Fig. 19B, biotinlabeled rCBD was bound to native type I collagen, indicating the putative collagen
binding domain. BSA, serving as the negative control (19A), did not bind native type I
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collagen, confirming specificity.

FIG. 19. Collagen binding Assay. The collagen binding property was identified for the
putative collagen binding domain in WapA by an adaptation of the dot immunobinding
method, but using Biotin conjugated recombinant CBD protein in place of the primary
antibody. A: No binding was detected with BSA used as a negative control. B: Binding
of soluble native type I collagen to rCBD protein was observed.

Quantitative analysis of collagen binding property of WapA
The WapA protein was evaluated for its ability to bind soluble collagen
immobilized onto a microtiter plate in a concentration-dependent manner. The putative
rCBD in WapA bound quantitatively to the immobilized collagen type I, whereas no
significant concentration-dependent binding was observed to the BSA (Fig. 20). Relative
binding was measured by monitoring absorbance at 405 nm following the alkaline
phosphatase reaction. Data points represent the means of OD405 nm values + standard
deviation from 3 independent experiments.
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FIG. 20. Binding of recombinant putative CBD of WapA protein to native type I
collagen used at different concentrations. Wells coated with BSA were used as the
negative control. Serially diluted, biotin-labeled rCBD protein was added to the wells in
a volume of 100 µl, and the bound protein was detected by AP-streptavidin by reading
the absorbance of the reaction mixture at 405 nm. Data are plotted as the mean values of
three experiments.

Cloning of truncated wapA genes into pcDNA3.1/V5/His-TOPO
After transformation of E. coli Top 10 with the eukaryotic expression vector
pcDNA3.1/V5/His-TOPO containing a truncated wapA gene, wapA-E or wapA-G,
plasmid DNA was isolated from the recombinant clones and amplified by PCR using a
forward primer specific to the T7 sequence of the vector upstream of the multicloning site
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and a reverse primer specific to the S. mutans gene insert. Analysis of the PCR products
by agarose gel electrophoresis showed that both constructs contained a DNA insert of the
correct size and in the correct orientation (Fig. 21). The complete nucleotide sequence of
these fragments was confirmed (Fig.22 and Fig. 23).

FIG. 21. Insertion of wapA-E and wapA-G fragments containing an initiation codon into
the pcDNA3.1 eukaryotic expression vector. Confirmation of the correct orientation of
the inserts. The PCR amplification of wapA-E and wapA-G DNA with different
combination of primers. Lane 1, Molecular mass markers, Lanes 2 and 3, a forward T7
primer specific to the sequence of the vector upstream of the cloning site with BGH
reverse for downstream of the cloning site for each truncation; Lane 4, Forward wapA-E
specific primer with BGH reverse primer; Lane 5, Forward wap-G primer with BGH
reverse primer; Lane 6, a forward T7 primer with wapA-E specific reverse primer; Lane
7, a forward T7 primer with wapA-G reverse primer; Lane 8, forward wapA-E primer
with reverse wapA-E; Lane 9, forward wapA-G primer with reverse wapA-G.
71

1
51
101
151
201
251
301
351
401
451
501
551
601
651
701
751
801
851
901
951
1001
1051
1101
1151
1201
1251
1301
1351
1401
1451

gagccaagct
agtgtggtgg
acggcttcta
taaggctgtt
tcccagatga
ccagagcaat
caatgggcaa
taacagttac
atgacattaa
tggtgttgta
aagacaaaga
caggataaaa
caaacaaggt
atcaagaaat
gctggtgatg
tgaggatttt
caacaggatt
atctcttata
cagcaacact
caggctacgc
aagaggcaag
gacaacagaa
cagctactag
tctcaaacga
agtaaccaag
cagggctttt
gtctatttct
gcacagtggc
ctatccctaa
caccatcacc

ggctagttaa
aattgccctt
tcacaaaatc
aattattggg
agtcagtatt
tacaatttac
ttagctggta
ctttactgat
attttaatgc
aactttaact
tattacgcca
gtaatcctgg
gctattgata
cgtaaaagat
atgttgacag
tcaaaaaatg
tacctataca
ctactcgttt
attgctattt
tcgtattgaa
cagaaacaac
acaagtagta
cacaacagga
atgttccgac
caaaaagcga
gttaactact
atagaacacg
ggccgctcga
ccctctcctc
attgagttta

gcttggtacc
accatggacc
agatggtaca
aaccactttc
aaggctgggg
gactgctcta
aagcaacaac
atttttgaaa
acaattgaat
ataataatgt
ataagtccag
tttgattcac
atttgacttt
tccttggttg
tttagatgaa
ttacttatca
attccaggat
aacttcttct
caggaaataa
tccgcatatg
aactgttact
caacaaataa
gcttcaacaa
aacaacaaac
aatttgtttt
gtaggtcttg
tcgttaaaag
gtctagaggg
ggtctcgatt
aaccc

gagctcggat
aagtcacaaa
gcactttcta
tttcagtaat
atactttaac
actttcgatg
tgatcctaat
aactgcctaa
cataacaata
tgcttatagt
atgttaacaa
tggaaagttc
gactgatgtt
ctgcacgctt
gctgcttcgc
aactaatgat
ccagtaacaa
caatctgctg
tattaattat
gtagagctag
gaaacaacaa
taattcaact
cacaaacaaa
ataacaacaa
accatcaaca
taattgttgc
ggcaattctg
cccgcggttc
ctacgcgtac

ccactagtcc
ttatacaaat
atgatccatc
tctattactt
cattaagttg
ttatgcatac
acaggagaag
tgataaggct
tttctattcc
tcttatgtta
agtgggttat
tcatcaacaa
gtcggagaag
gcagtacatt
gaccttatgc
ttaggattga
cgctatcttt
gtaaagatgt
tccaatcaaa
ttctagagta
ctagtgaagc
actacagaaa
aacgactgct
cttcaaaaca
ggtgaacaag
tgtggcaggt
cagatatcca
gaaggtaagc
cggtcatcat

FIG. 22. Nucleotide sequence of the recombinant wapA (wapA-E) cloned into a
eukaryotic expression vector, pcDNA3.1. The underlines indicate the regions used as
primers for the amplification of the wapA. The Kozak sequence, initial Met, and
terminal codon are highlighted in yellow.
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1
51
101
151
201
251
301
351
401
451
501
551
601
651
701
751
801
851
901
951
1001
1051
1101

gagccaagct
agtgtggtgg
acggcttcta
taaggctgtt
tcccagatga
ccagagcaat
caatgggcaa
taacagttac
atgacattaa
tggtgttgta
aagacaaaga
caggataaaa
caaacaaggt
atcaagaaat
gctggtgatg
tgaggatttt
caacaggatt
atctcttata
cagcaacact
caggctacta
tcgagtctag
cctcggtctc
tttaaaccc

ggctagttaa
aattgccctt
tcacaaaatc
aattattggg
agtcagtatt
tacaatttac
ttagctggta
ctttactgat
attttaatgc
aactttaact
tattacgcca
gtaatcctgg
gctattgata
cgtaaaagat
atgttgacag
tcaaaaaatg
tacctataca
ctactcgttt
attgctattt
aaagggcaat
agggcccgcg
gattctacgc

gcttggtacc
accatggacc
agatggtaca
aaccactttc
aaggctgggg
gactgctcta
aagcaacaac
atttttgaaa
acaattgaat
ataataatgt
ataagtccag
tttgattcac
atttgacttt
tccttggttg
tttagatgaa
ttacttatca
attccaggat
aacttcttct
caggaaataa
tctgcagata
gttcgaaggt
gtaccggtca

gagctcggat
aagtcacaaa
gcactttcta
tttcagtaat
atactttaac
actttcgatg
tgatcctaat
aactgcctaa
cataacaata
tgcttatagt
atgttaacaa
tggaaagttc
gactgatgtt
ctgcacgctt
gctgcttcgc
aactaatgat
ccagtaacaa
caatctgctg
tattaattat
tccagcacag
aagcctatcc
tcatcaccat

ccactagtcc
ttatacaaat
atgatccatc
tctattactt
cattaagttg
ttatgcatac
acaggagaag
tgataaggct
tttctattcc
tcttatgtta
agtgggttat
tcatcaacaa
gtcggagaag
gcagtacatt
gaccttatgc
ttaggattga
cgctatcttt
gtaaagatgt
tccaatcaaa
tggcggccgc
ctaaccctct
caccattgag

FIG. 23. Nucleotide sequence of the recombinant agA (wapA-G) cloned into a
eukaryotic expression vector, pcDNA3.1. The underlines indicate the regions used as
primers for the amplification of the agA. Yellow highlight shows the Kozak sequence,
initial Met, and terminal condon.

Quality control of plasmid production for immunization
The plasmid DNA production must include a good quality control process in
order to assure the plasmid DNA, especially when used as a therapeutic agent including
vaccination, is free of any contaminats, which include proteins, RNA, endotoxins,
genomic DNA of the host cell, or any components used in the purification process.
Purification of supercoiled plasmid without containing other isofoms such as nicked,
linear, dimers or concatemers plasmids is an essential factor for quality control of
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plasmid production, as well as function as a reproducible, scalable and economical
purification process. Plasmid isolation was performed using the Qiagen procedure
approved to produce plasmid DNA for human clinical Phase I studies in the U.K. (14)
and other European countries, as well as in the United States by the FDA (49).
Supercoiled plasmid and any other isoforms were analyzed by running total
plasmid DNA in 1% agarose gel electrophoresis (Fig. 24A). Plasmid DNA identity and
quality were accessed through restriction analysis by BstXI digest of the parental vector
and wapA or agA DNA vaccine constructs (Fig. 24B). DNA purity was assessed by
using spectrophotometric analysis and calculation from its absorbance ratio of
260nm/280nm.
A.

B.

FIG. 24. Agarose gel electrophoresis and restriction enzyme digestion of pcDNA3.1wapA or pcDNA3.1-agA for assuring the quality of DNA vaccines. A. Lane 1, λ DNAHind III Digest. Lane 2, pcDNA3.1-wapA. Lane 3, pcDNA3.1-agA. Lane 4, pcDNA
3.1 parental vector. B. Lane 1, 100 base pair ladder. Lane 2, pcDNA3.1-agA-BstXI
digest. Lane 3, pcDNA3.1-wapA-BstXI digest. Lane 4, pcDNA3.1-BstXI digest.
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Expression of WapA and AgA by dot immunobinding assay
The expression of wapA and agA genes was investigated by immunodot analysis
of the sonic extract of transfected CHO cells against a rabbit antiserum to the S. mutans
cell wall. Chemiluminescence detection showed a high level of expression of both wapA
and agA. No reaction was obtained with the negative control CHO cells (Fig. 25).

A

B

C

D

E

FIG. 25. Immunodot analysis. The sonic extracts were dotted onto a piece of
nitrocellulose filter. Expression was detected by chemiluminescence substrate ECL for
HRP. (A) A 4B2 clone sonic extract (positive control). (B) A wapA-E transfected CHO
cell. (C) A wapA-G transfected CHO cell. (D) CHO cell treated with the lipid alone
(negative control). (E) Untransfected CHO cells (negative control).

Western immunoblot analysis of WapA and AgA expressed in transfected CHO cells
To determine the molecular size of the proteins expressed in transfected CHO
cells, Western immunoblot analysis was performed on aliquots of the cell sonic extract.
Proteins with the anticipated molecular weights of 52,000 and 29,000 were observed with
the transfected CHO cell samples, but not with the negative control untransfected CHO
cells (Fig. 26).
75

FIG. 26. Western immunoblot analysis of wapA-E and wapA-G gene expression using
rabbit antiserum to S. mutans cell wall antigens in CHO cells at 24 h post-transfection.
Lane 1, WapA-E sonic extract. Two bands of 52 and 29 kDa were obtained
corresponding to WapA and AgA, respectively. Lane 2, WapA-G sonic extract. The
anticipated 29-kDa band was obtained (smaller bands are probably attributable to
proteolytic degradation). Lane 3, CHO cell treated with the lipid alone as a negative
control. Lane 4, Untransfected CHO cells as a negative control.

In situ immunochemical staining of transfected CHO cells
To localize the WapA and AgA protein in transfectants, immunochemical staining
was performed using a rabbit antiserum to S. mutans cell wall antigens followed by an
alkaline phosphatase-conjugated goat antibody to rabbit immunoglobulins. Detection
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was performed using the chromogenic substrate fast red stain. The presence of antigen
was identified by a red coloration. The WapA protein was found mainly associated with
the CHO cell membrane and budding vesicles, whereas AgA was found in transfected
cells and extracellular surroundings (Fig. 27). Thus, the wapA and agA gene constructs
were efficiently taken up by CHO cells through lipid-mediated transfection and expressed
in these eukaryotic cells.
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A

B

C
D
FIG. 27. In situ expression of WapA and AgA at 24 hours post-transfection. Transfected
CHO cells were fixed on a slide with cold acetone, blocked with skim milk, and
immunochemically stained with antibody to S. mutans cell wall. Fast Red RC was used
as a substrate for alkaline phosphatase. (A) A CHO cell treated with the lipid alone as a
negative control. (B) Expression of AgA in transfected cells and extracellular medium.
(C) Expression of WapA in transfected cells and budding vesicles. (D) Expression of
WapA in large vesicles. (A, B and C were identified on the light microscope at X400 and
photographed at X1000).
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Optimization of pcDNA-lipid complex
HeLa cells were transiently transfected to determine the optimum ratio of
pcDNA-lipid complex. The highest transfection efficiency was obtained with 2 µg
pcDNA and 10 µg DMRIE-C, the ratio corresponding approximately to the ratio in
molarity of 1:2 of pcDNA and DMRIE-C. Decreased β-galactosidase activity was
indicative of cell death (Fig. 28).
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FIG. 28. Optimization of DMRIE-C Reagent and pcDNA ratio for transfection. In order
to determine the optimal DMRIE-C formulation, different pcDNA3.1-βgal
DNA:DMRIE-C lipid ratios were tested in Hela cells. At 24 h post-transfection, cells
were solubilizd and assayed for the β-galactosidase activity at 415 nm with a
spectrophotometer. Data are means and standard deviation of duplicates.

Dot immunobinding assay
Four weeks after the booster immunization, mice immunized with plasmid
containing wapA or agA complexed with DMRIE-C showed the presence of anti- AgA
salivary sIgA by immunodot analysis using a HRP-conjugated anti-mouse IgA and a
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chemiluminescence substrate for HRP (Fig. 29). No reaction was detected in the saliva
obtained from the control mice.

FIG. 29. Immunodot analysis of anti-WapA and AgA salivary IgA production. Purified
GST-AgA fusion protein was dotted onto a piece of nitrocellulose filter in line 2.
Purified GST only was used as a control in line 1. The filter was incubated overnight
with the saliva (1:2 dilution in PBS) of mice that were immunized with (A) PBS, (B)
DMRIE-C lipid, (C) pcDNA3.1 vector with DMRIE-C, (D) WapA DNA vaccine
construct with DMRIE-C, and (E) AgA DNA vaccine construct with DMRIE-C.
Chemiluminescence detection showed the presence of anti-WapA and AgA salivary IgA
in 2D and 2E. No reaction was obtained with the saliva of control mice.

Humoral immune responses induced by DNA vaccines
To access the level of humoral immune response after DNA immunization, serum
or saliva was collected from the control mice and the mice immunized with pcDNAwapA or pcDNA–agA at various time points after the second immunization. ELISA of
the saliva obtained showed a significantly higher level (P < 0.05) of antigen-specific IgA
in the immunized mice as compared to the background level in the control group (Fig.
80

30A). Similarly, the levels of antigen-specific IgG were observed in the serum of the
immunized mice as compared to that of the control animals (P < 0.05) (Fig. 30B). Both
salivary IgA and serum IgG titers were higher in the samples collected from the pcDNAwapA immunized mice as compared to those immunized with pcDNA-agA vaccine (P <
0.05) (Fig. 30).
A.

B.

FIG. 30. Salivary IgA and serum IgG responses in mice. Following intra nasal
immunization with pcDNA-wapA or pcDNA-agA, pooled saliva (A) and serum (B)
samples were analyzed by ELISA using plates coated with recombinant AgA. Mice
immunized with either pcDNA-wapA or pcDNA-agA showed a significantly higher
signal than the background level (control mice), both in saliva and serum (P < 0.05).

Western immunoblot analysis of antibody response against AgA
Analysis of the saliva of the mice immunized with pcDNA-agA or with pcDNAwapA by Western immunoblot showed the presence of sIgA binding to the GST-WapA
antigen band of approximately 58 kDa (Fig. 31).
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FIG. 31. Western immunoblot analysis of salivary sIgA Abs to wapA and agA DNA
vaccines. The results showed the anticipated antigen bands (GST-AgA fusion protein of
approximately 58 kDa) with the saliva of mice immunized with agA-pDNA (Lane 3) or
with wapA-pDNA (Lane 5). No band was obtained with either mouse saliva against the
extract of the control E. coli harboring empty vector (lanes 4 and 6). As anticipated, no
band was obtained with the saliva of the control mice (Lane 1 and 2).

Induction of S. mutans WapA
The WapA is involved in sucrose-dependent adherence and aggregation (101). In
order to determine whether sucrose induces further the expression of WapA, S. mutans,
Western blot analysis was performed on sonic extracts of each culture grown with or
without sucrose presence. Expression of S. mutans WapA was strongly enhanced in
presence of 2% sucrose, suggesting WapA expression is regulated by sucrose (Fig. 32).
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FIG. 32. Expression of WapA in presence of sucrose. Enhanced WapA expression was
shown in the S. mutans culture grown in presence of 2% sucrose.

Western immunoblot analysis of antibody response against WapA
Reactivity against WapA was higher with the anti-WapA antibody than with the
reactivity of the anti-AgA, suggesting a stronger reaction is attributable to the additional
epitopes seen in WapA but not in AgA (Fig. 33).

FIG. 33. Western blot analysis of S. mutans WapA using polyclonal antiserum raised
against AgA or WapA. Stronger immunoreactivity was shown with anti-WapA serum
that that of anti-AgA.
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Sucrose-dependent adherence inhibition assay
Saliva of the immunized mice, with pcDNA-wapA or pcDNA-agA, was evaluated
for the ability to inhibit the S. mutans in vitro sucrose-dependent adherence. A
significantly higher inhibition of adherence (P<0.05) was obtained with the saliva of the
mice immunized with pcDNA-wapA (21% inhibition) as compared to the Saliva of the
mice immunized with pcDNA-agA (7% inhibition) shown in Table 3.

TABLE 3. EFFECT OF SALIVARY IgA PRODUCED IN RESPONSE TO
IMMUNIZATION ON BACTERIAL ADHERENCE
Immunization
Mean % adherent cells/total cells + SD b
Group
Treatment a
A
pcDNA Vector only ……………………………………… 61.11 + 1.75
B
pcDNA-wapA…………………………………………… 48.53 + 1.36
C
pcDNA-agA……………………………………………… 57.00 + 1.44
a
Saliva collected was diluted 1:2 in PBS and added to triplicate S. mutans culture wells.
b

Significant inhibition (P<0.05) of S. mutans in vitro sucrose-dependent adherence was

observed with the saliva of mice immunized with pcDNA-wapA (B), and to a lesser
extent with the saliva of mice immunized with pcDNA-agA (C) or with pcDNA vector
alone (A)

Dextran-binding properties
Analysis of recombinant WapA or AgA for the ability to bind biotin-labeled
dextran showed that WapA bound dextran, but AgA did not. As anticipated, no dextranbinding activity was observed with GST used as a negative control (Fig. 34).
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FIG. 34. Dextran-binding assay. The dextran-binding property was identified on GST
fusion proteins containing WapA or AgA against the Biotin-dextran conjugate using the
Dot immunobinding method. The WapA showed a capacity to bind dextran (1), but the
AgA did not (2). GST only was dotted as a control (3).

Cloning and sequencing of il-5 and ctb recombinant genes
The orientation and identity of the il-5 cDNA and ctb gene clones were confirmed
by the nucleotide sequencing (Fig. 35). The cloned il-5 cDNA was 402 bp of ORF
without signal peptide, and it encoded 133 amino acid residues. The sequencing of the
ctb clone showed correct identity of the ctb gene insert including 312 nucleotides
encoding 103 amino acids.
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A.
TTAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAATTGCCCTTACCATGAGAAGGATGCT
TCTGCACTTGAGTGTTCTGACTCTCAGCTGTGTCTGGGCCACTGCCATGGAGATTCCCATGAGCACAGTGG
TGAAAGAGACCTTGACACAGCTGTCCGCTCACCGAGCTCTGTTGACAAGCAATGAGACGATGAGGCTTCCT
GTCCCTACTCATAAAAATCACCAGCTATGCATTGGAGAAATCTTTCAGGGGCTAGACATACTGAAGAATCA
AACTGTCCGTGGGGGTACTGTGGAAATGCTATTCCAAAACCTGTCATTAATAAAGAAATACATTGACCGCC
AAAAAGAGAAGTGTGGCGAGGAGAGACGGAGGACGAGGCAGTTCCTGGATTACCTGCAAGAGTTCCTTGGT
GTGATGAGTACAGAGTGGGCAATGGAAGGCTGAAAGGGCAATTCTGCAGATATCCAGCACAGTGGCGGCCG
CTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGC
GTACCGGTCATCATCACCATCACCATT

B.
TTAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAATTGCCCTTACCATGACACCTCAAAA
TATTACTGATTTGTGTGCAGAATACCACAACACACAAATATATACGCTAAATGATAAGATATTTTCGTATA
CAGAATCTCTAGCTGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAATTTTTCAAGTAGAA
GTACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCTGAGGATTGC
ATATCTTACTGAAGCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCATGCGATTGCCGCAA
TTAGTATGGCAAATTAAAAGGGCAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGC
CCGCGGTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCA
CCATCACCATT

FIG. 35. Nucleotide sequence of il-5 or ctb gene insert. The il-5 cDNA or ctb gene
subunit was cloned into the pcDNA3.1 mammalian expression vector and sequenced. The
coding regions, including the ATG start codon, are in red, and the Kozak sequence is
underlined. The primers used are indicated in blue.

Western immunoblot analysis of the purified GST-CTB fusion protein
The purified GST-CTB fusion protein was confirmed by the Western immunoblot
with monoclonal antibody to Ctb. The 40-kDa band was identified on the nitrocellulose
lines containing purified GST-CTB fusion protein or lysate of E. coli containing the
construct. No band was shown on the line with purified GST (Fig. 36).
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FIG. 36. Western immunoblot analysis of purified GST-CTB fusion protein. Specific
binding of the anti-CTB monoclonal antibody to the cloned and purified GST-CTB
protein (Line 2). No immunoreactivity was shown to the purified GST protein (Line 3).
The molecular masses standards (lane 1) are indicated (in kilodaltons) on the left of the
blot.

Expression of recombinant WapA or AgA
WapA and AgA are expressed as GST-fusion poteins in the E. coli recombinant
clones WapAE and WapA-G, respectively. Expression of both antigens was observed
(Fig. 37 and Fig. 38).
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FIG. 37. SDS-PAGE analysis of the GST-wapA fusion protein expression. A highly
expressed truncated wapA-G gene as GST fusion was used as the coating antigen in an
ELISA assay. Lane 1, E. coli BL 21 lysate. Lane 2, a soluble sonic extract containing
GST-wapA-G. Lane 3, GST-wapA-G protein purified from the soluble fraction. Lane 4,
M.W. marker.

Fig. 38. Expression of wapA and agA genes as GST fusions. SDS-PAGE of purified 29
kDa GST (lane 1), 81 kDa GST-WapA (lane 2), and 58 kDa GST-AgA (lane 3) are
shown on coomassie blue stained gel. Molecular weight standards were run in lane 1.
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Production of DNA vaccine
The recombinant E. coli TOP10 containing the target DNA was cultured in an LB
medium containing ampicillin added at 50 micrograms per milliliter, and plasmid DNA
was isolated by the modified alkaline lysis method using a kit from Qiagen (HiSpeed
Maxi Kit), Valencia, CA. The average yield of plasmid DNA containing the wapA gene
(pcDNA-wapA) was 2 mg/L E. coli culture, whereas that of the plasmid containing the
agA gene (pcDNA-agA) was only 0.92 mg/L. One reason for the low yield of pcDNAagA is the tendency of the recombinant E. coli to lyse. In order to improve the yield of
pcDNA-agA, the antibiotic chloramphenicol was added to the culture. As a result, the
yield of plasmid copies was improved by approximately 2.5 fold (2.3 mg/L E. coli
culture). Hence, we have established the conditions for the obtaining of comparable
levels of production of pcDNA-wapA and pcDNA-agA.
Production of Protein vaccine
The proteins WapA and AgA were obtained separately, each as a fusion protein
with the enzyme glutathione S-transferase (GST), respectively designated as WapA-GST
and AgA-GST. The yield of these proteins was determined by optical density readings at
280nm, and calculated based on the extinction coefficient of GST (1 OD280 = 0.5 mg
protein/ml). The fusion proteins were purified by affinity column chromatography on
GST-Sepharose (Promega, Madison WI) and purity was demonstrated by SDS-PAGE,
where a single protein band was obtained for each GST-fusion protein. Originally, the
yield of AgA-GST and WapA-GST was 2.5 mg/L and 1.2 mg/L, respectively. One
reason for the lower yield of WapA-GST was due to the insolubility of WapA, since this
protein contains an extra hydrophobic membrane-binding region at the C-terminal end as
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compared to AgA. Sarkosyl was used to solubilize the E. coli membrane and improve
the recovery of WapA-GST. The results showed a two-fold increase up to 2 mg/L.
Immunodot analysis
The presence of anti-WapA salivary IgA was detected by Immunodot analsis.
Weak staining was shown in the saliva from the DNA vaccine immunized mice while a
much stronger reaction was obtained with the protein vaccinated mice (Fig. 39). No
reaction was detected from the saliva of the negative control or that of the DNA vaccine
alone without cationic lipid.

FIG. 39. Immunodot analysis. Saliva from immunized mice were tested for
immunogenicity of specific S-IgA against WapA. Group 1 mice immunized with
pcDNA-wapA alone (2), or with pcDNA-il-5 (3) or pcDNA-ctb (4) showed weak
immunogenicity to WapA. Group 2 mice immunized with AgA (6) or WapA (7) showed
strong reaction to WapA. Group 3 mice that is primed with pcDNA-wapA and boosted
with WapA protein (5) revealed strong immunogenicity to WapA. No immunogenicity
was shown for non-immunized (1) or WapA DNA vaccine only without adjuvant (8).

Immunomodulatory effect on humoral immunity
To investigate the influence of il-5 or ctb co-immunization on the level and
duration of salivary IgA response, saliva from the control and immunized mice with or
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without the adjuvant was analyzed using an ELISA assay. Co-immunization with
pcDNA-il-5 resulted in a significant (P < 0.05) but temporal sIgA response after boosting
with a third injection of DNA as compared to that of the control mice group (Fig. 40A).
This was followed by a drop in the level of sIgA with the additional booster, indicating
that the booster effect was aborted and, therefore, no memory immune response was
elicited. The level of sIgA antibody induced by pcDNA-ctb as an adjuvant was improved
more rapidly and consistently as compared to that of the control or pcDNA-il-5 coimmunization (Fig. 40A).
Mice primed with pcDNA-wapA followed by the WapA boost produced sIgA
levels comparable to mice receiving 2 WapA doses (Fig. 40B). The antigen-specific
antibody was not affected in the groups administered with DNA only without adjuvant
and the non-immunized group (Fig. 40).
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A.

B.

FIG. 40. WapA-specific sIgA antibody response in the saliva of mice immunized with
DNA or protein vaccine. Levels of the antigen-specific S-IgA was determined in the
saliva of immunized mice given pcDNA-wapA alone, or with pcDNA-il-5 or pcDNA-ctb
(A) or primed with pcDNA-wapA and boosted with WapA or WapA and CTB (B) by the
i.n route. Each vaccine was injected biweekly, as shown by black arrows, for a total of
four inoculations. Each point is the mean of triplicate values.

92

DISCUSSION

Dental caries is a significant health problem in humans and treatment is costly due
to the high prevalence in the population. Despite longstanding effort at the development
of a caries vaccine, an efficacious vaccine protocol has not yet been developed. The
establishment of an effective mucosal vaccine would be an exceptionally significant
accomplishment that would greatly enhance the ability to provide preventive vaccination
for this disease. This is especially true for the groups at risk such as underserved
communities which do not have access to water fluoridation and periodical preventive
dental care, and children and adults with medical problems or receiving medical
treatments that reduce salivary flow. Once developed, the dental vaccine should also
serve as a model for the preparation of similar vaccines against other infectious agents,
particularly those infecting the oral cavity.
The overall objective of this study was to develop a novel mucosal vaccine that is
safe, cost-effective and efficacious at inducing protective immunity against dental caries.
A number of virulence factors have been identified as candidate vaccine antigens, most of
which have been cloned and sequenced, and some have been tested with much promise.
Since salivary immunoglobulin A (IgA) to various S. mutans adherence and aggregation
factors has been showed to confer protection against S. mutans infection, induction of
mucosal immunity has become the main target for dental caries vaccine development (37,
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120, 122). The target antigens used in this study were the S. mutans antigen A (AgA), a
recognized candidate vaccine antigen, and its precursor the wall-associated protein A
(WapA), a factor involved in colonization and build up of dental plaque. Previously,
WapA gene and the truncated agA gene had been cloned into a high expression vector for
expression as Glutathione-S-Transferase fusion proteins to improve yield and facilitate
purification (146). However, considering that the costs associated with the extraction,
purification and storage of recombinant antigens and antibodies can be an obstacle to
mass immunization, it is necessary to explore alternative approach.
With recent advances made in the construction of DNA vaccines comes the hope
for a more economical way to immunize against infectious disease. In the present study,
genetic immunization using naked DNA vaccine was used as an alternative method of
inducing mucosal immunity characterized by the induction of secretory IgA against S.
mutans. DNA vaccine is both potentially safer and more economical than conventional
vaccines when considering the ease of isolation of plasmid DNA, low cost of massproduction, stability at extreme temperatures, ease of administration, and potential for
induction of long-lasting immunity without causing any severe side effects (1, 39).
Therefore, the prospect of a DNA vaccine against dental caries is particularly attractive
due to the high incidence of this disease in the world, with populations of low
socioeconomic status being at the highest risk.
DNA vaccines induce both specific antibody and cell-mediated immune responses
(27). However, their use has been mainly focused on viral infections (81). DNA
vaccines against bacterial infections have been limited to intracellular bacterial pathogens
such as Mycobacteria spp. or Salmonella spp. where cytotoxic or a Th1 type T cells
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confer protection (130). Moreover, induction of mucosal immunity against extracellular
bacterial infection where secretory IgA mediates resistance has been rarely studied.
The feasibility of DNA vaccine efficacy was demonstrated in terms of inducing
specific mucosal immunity against S. mutans, an extracellular bacterium, and relative
immunogenicity of full-length and C-terminal truncated wapA was compared and
evaluated.
Further exploration was made to test the efficacy of two forms of vaccine; Gene
versus Protein in inducing specific sIgA response. The efficacy of co-immunization with
genetic adjuvants at enhancing salivary IgA response was also investigated. A number of
cytokines have been identified as enhancing the mucosal IgA response to DNA vaccines,
notably IL-5 in mice (102, 139). Intranasal administration of recombinant adenovirus
vectors expressing IL-5 has been shown to enhance secretory IgA response to the
adenovirus in the lung (102). Increased IgA response to Salmonella LPS has also been
observed in mice immunized with the bacterial strain engineered to express murine IL-5
(138). IL-5 was chosen over other cytokines as it has been found to be the primary
cytokine inducing the generation of IgA producing B cells in mice.
Effects of co-immunization with either gene or protein of a CTB subunit were
studied. CTB is a proven adjuvant for the induction of a mucosal response to a proteinbased vaccine in mice (142). Unlike CT and CTA subunits, CTB is not toxic, and hence
has been considered as a good candidate adjuvant for human use (145). Bergquist et al.
(10), using recombinant CTB in intranasal immunization of humans, did not observe any
systemic adverse reactions, but only local irritations of short duration at high doses
(1,000 µg per dose) in all volunteers. At a lower dose (100 µg), the local reaction was
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mild and tolerable, and occurred only in approximately one third of the subjects.
In a study conducted by Johansson et al. (52), 21 female volunteers were
administered nasally 250 µg of recombinant CTB using an atomizer, and no apparent side
effect was reported. CTB was also found to be safe in the immunization of Israeli young
adults against enterotoxigenic E. coli (16). By using pcDNA-ctb as an adjuvant in DNA
immunization, it was possible to not only compare the efficacy of protein versus DNA
vaccine, but also that of protein versus DNA adjuvant. The enhancement of mucosal
immunity to protein conjugated with CTB was due to two functions of CTB: (1)
transmucosal carrier, and (2) immuno-stimulatory molecule. In immunization with
pcDNA, delivery of pcDNA across the mucosal barrier is mediated by DMRIE-C, thus
any enhancement obtained by co-immunization with pcDNA-ctb will be attributable to
the strong immunogenic properties of CTB.
Cloning of the truncated wapA genes, wapA-E and wapA-G, into the eukaryotic
expression vector pcDNA3.1/V5/His-TOPO was completed, and the genes were shown to
be inserted in the correct orientation. To test the expression of the cloned genes, CHO
cells were used as hosts in transfection studies. The cationic lipid pfx8 was used, as it has
been reported by the manufacturer to work best for CHO cells. Indeed, transfection of
CHO cells was successful, and the cloned genes were expressed as anticipated. It is
noteworthy that the wapA-E gene product (WapA-E), corresponding to the S. mutans
WapA, was expressed in the transfected cells and budding vesicles, probably from cells
undergoing apoptosis, whereas the wapA-G gene product (WapA-G), corresponding to
the S. mutans AgA, was found in both the cells and the surrounding medium.
The differential expression of WapA and AgA may be attributable to the presence
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of the hydrophobic C-terminal end of WapA, allowing this molecule to interact with
hydrophobic components in the host cell membrane. The AgA protein is truncated in this
hydrophobic region and hence is more soluble and may be released from leaky or lysed
cells.
Whether the genes are expressed as soluble or cell-and vesicle-associated
proteins, it is reasonable to anticipate an antibody response, as previously obtained by
immunization with the WapA and AgA proteins. In fact, both cellular and humoral
immune responses were obtained by immunization with DNA vaccines, indicating that in
the host cells, the foreign proteins were processed both through the endogenous pathway
of antigen processing, and presented associated with MHC-I, or through release and
uptake by antigen-presenting cells for processing by the exogenous pathway and
presentation in association with MHC-II (61). The present study illustrated two ways by
which foreign proteins could be released from the host cells. The immunization study
showed that it was feasible to induce a mucosal response to S. mutans antigen by
intranasal administration of naked DNA vaccine containing the wapA gene or its
truncated derivative agA gene. Both DNA constructs induced antigen specific sIgA
antibodies in the saliva of the immunized animals, with a higher antibody titre observed
with pcDNA-wapA as compared to pcDNA-agA.
It was hypothesized that due to its larger size and hydrophobicity, due to the
presence of a membrane and wall-spanning region, WapA may be more immunogenic
than its hydrophilic truncated derivative AgA. Data from a previous in vitro transfection
study showed that WapA was found expressed in budding vesicles (presumably apoptotic
bodies), whereas AgA was diffused in the extracellular medium. Such an occurrence in
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vivo should facilitate the phagocytosis and processing of apoptotic bodies and the
presentation of antigen peptides to T helper cells by macrophages. This hypothesis was
further supported by the sequence analysis of WapA and AgA using virtual matrices
algorithms. The results obtained revealed putative binding sequences within the
hydrophobic C-terminal end of WapA, along with the rest of the sequences, based on
MHC binding motifs for known major histocompatibility complex class II binding
alleles. Those predicted MHC class II ligands corresponded with promiscuous binding
motifs associated with 51 MHC class II alleles; one of the most prominent promiscuous
binders was located at residues 400 to 409, within the C-terminal end. Those
promiscuous binding motifs allow for a large degree of compatibility between the antigen
peptide sequence and dimeric MHC II molecule (121). The resulting peptide-MHC II
complexes are delivered to the membrane for detection by CD4+ T cells and induce
humoral immune responses (99).
Most of the peptides presented by MHC class II molecules are derived from the
endocytosis and processing of extracellular proteins (99, 122). Previously, it was
demonstrated by others that endogenous proteins produced by a DNA vaccine could be
released from transfected cells and uptaken by antigen-presenting cells for processing by
the exogenous pathway and presentation in association with MHC class II. Moreover, in
the host cells, endogenous antigens enter the MHC Class II processing and presentation
pathways much more efficiently than the endocytosis and processing of the same protein
from the extracellular compartment (12, 95, 115). Another major factor affecting the
antibody response is transfection efficiency (29, 43, 114). The present study also
demonstrated that transfection efficiency of HeLa cells was dependent on the ratio of
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pcDNA:DMRIE-C starting at 1:1 (w/w) and reaching an optimal level at 1:5, then
decreasing thereafter. The decrease in transfection efficacy and expression was
associated with cell death due to the toxicity of DMRIE-C at high dose.
In addition to the above, the inhibition of S. mutans adherence to the culture
vessel when grown in the presence of sucrose by a salivary antibody of mice immunized
with pcDNA-wapA, and not by the salivary antibody of the mice immunized with
pcDNA-agA, further demonstrated that WapA was a better candidate vaccine antigen
than AgA. Dot immunobinding assay where the WapA in its larger precursor form
showed a glucan-binding property, but not the 29-kDa C-terminal truncated version
(wapA-G) encoding the AgA, supports this view. These findings are in agreement with
the previous data in an experiment where WapA, but not the AgA, showed a binding
affinity to various dextran matrices (23). The work presented here explores the feasibility
of genetic immunization against S. mutans. DNA vaccine containing the S. mutans wallassociated protein A gene (wapA) were proven to be better immunogens than others
which contained the truncated derivative corresponding to the antigen A gene (agA) for
the reasons described above.
In the present study, we further evaluated if co-immunization with genetic
adjuvant would enhance the levels of sIgA response elicited by the caries DNA vaccine
containing the WapA gene. Attempts were also made to compare the efficacy of DNA
versus protein in inducing the WapA-specific sIgA response. Our data shows that a DNA
vaccine encoding WapA protein is less effective than a corresponding protein vaccine in
inducing mucosal antibody response. Furthermore, subsequent boosts with DNA vaccine
were not capable of amplifying Ab memory generated by the DNA vaccine prime,
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suggesting homologous DNA vaccine is not an efficient booster of immune memory.
Specific salivary IgA response was transiently enhanced by co-immunization with
IL-5 expressing plasmid, while comparatively steady increase was observed by a coimmunization with plasmid containing the CTB gene. This observation indicates that
expressed CTB may have continuing adjuvant activity by enhancing presentation of
expressed antigen released from transfected cells and by stimulating mucosal Th2-type
cytokine responses, such as IL-5, leading to increased mucosal IgA production. Antigenspecific IgA response was improved by the action of pcDNA-il-5 expression, indicating
immunomodulatory effect of the cytokine in improving isotype differentiation of B cells
to mucosal IgA formation. However, the IgA antibody response failed to be sustained,
probably due to the lack of booster effect in generating continuous IL-5 as seen with
pcDNA-wapA gene immunization.
Prime-boost immunization regimen of pcDNA-wapA priming, followed by
boosting with a WapA protein, showed considerable enhancement on the level that sIgA
produced, almost as high as protein-protein vaccination. Thus, pcDNA-wapA was shown
to be a valid candidate primary vaccine and that subsequent natural exposure to S. mutans
may provide the necessary boost to induce higher sIgA response.
It has been reported that plasmid DNA immunization predominantly induces a
Th1-type cellular immune response (104) over a Th2 type immune response that
produces humoral antibodies. The lower salivary IgA immune response generated from a
DNA vaccine might be due to the Th1-biased characteristic of the vaccine. Insufficient
memory response was consistently observed in other studies indicating that boosting may
not efficiently stimulate the memory B cells with the DNA vaccine (70, 107, 119).
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Indeed, the data demonstrated that intranasal immunization with a DNA vaccine followed
by a boost with the corresponding protein vaccine showes a significant enhancement of
the antigen-specific salivary sIgA response, a key factor for protective mucosal
immunity.
With recent advances in the understanding of B and T-cell memory, prime-boost
vaccination strategies appear to create a synergistic effect from the two vaccines, and the
quality and longevity of T-cell memory generated from DNA prime can be significantly
enhanced by subsequent protein boosting. From the experiments performed herein, we
have been able to establish an alternative, novel DNA vaccine strategy of inducing
mucosal immunity against S. mutans. Dental caries induction involves multiple S.
mutans proteins, and this study should serve as a model for the preparation of other gene
constructs to include in a combination dental DNA vaccine. The results obtained in this
study will have an impact on future vaccine development, not only against S. mutans, but
also against other pathogens utilizing the mucosal lining of the respiratory, gastrointestinal, and genito-urinary tract as a route of entry into the host.
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